Medicinal and edible plants in the treatment of dyslipidemia: advances and prospects

Ying Hu1,2,3†, Xingjuan Chen1†, Mu Hu1,2, Dongwei Zhang4, Shuo Yuan5*, Ping Li3,6* and Ling Feng1,2*

Abstract

Dyslipidemia is an independent risk factor of cardiovascular diseases (CVDs), which lead to the high mortality, disability, and medical expenses in the worldwide. Based on the previous researches, the improvement of dyslipidemia could efficiently prevent the occurrence and progress of cardiovascular diseases. Medicinal and edible plants (MEPs) are the characteristics of Chinese medicine, and could be employed for the disease treatment and health care mostly due to their homology of medicine and food. Compared to the lipid-lowering drugs with many adverse effects, such as rhabdomyolysis and impaired liver function, MEPs exhibit the great potential in the treatment of dyslipidemia with high efficiency, good tolerance and commercial value. In this review, we would like to introduce 20 kinds of MEPs with lipid-lowering effect in the following aspects, including the source, function, active component, target and underlying mechanism, which may provide inspiration for the development of new prescription, functional food and complementary therapy for dyslipidemia.

Keywords: Medicinal and edible plants, Dyslipidemia, Lipid-lowering, Signaling pathway

Introduction

Dyslipidemia is the metabolic disorder of plasma lipids and lipoproteins [1], and the overall prevalence rate of dyslipidemia among Chinese residents over 40 years old was 43% according to the latest cardiovascular health and disease report [2]. Dyslipidemia is considered as an independent risk factor of CVDs [3], which globally lead to high mortality, disability, and medical expenses [4, 5]. In addition, studies have revealed that the high non-high-density lipoprotein cholesterol was the main reason for ischemic heart disease and stroke, leading to approximately 3.9 million deaths throughout the world [6]. Since primary prevention plays a crucial role in decreasing the incidence of CVDs [7, 8], advances in modifying dyslipidemia are of great help to reduce morbidity and mortality associated with CVDs [4, 9].

Currently, as the first-line lipid-lowering drugs, statins have adverse reactions such as myalgia, liver damage, and diabetes, especially used in large doses [10–12]. Similar side effects such as myopathy, liver enzyme elevations, and cholelithiasis are also found in the progress of dyslipidemia therapy when the patients treated with fibrates [4, 13]. Although the targeted therapeutic drugs proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been developed, the high cost and unverified safety limit further clinical applications [4, 13]. In addition, unsatisfactory therapeutic effect and drug resistance were also found in some patients [14]. Obviously, the development of additional and alternative treatments is still highly necessary for dyslipidemia therapy.

Over the past 5000 years, traditional Chinese medicine (TCM) has been used to prevent and treat various diseases. Based on the abundant clinical experiences...
and researches, the efficacy and safety of TCM have been verified. For example, TCM has shown remarkably potential in the fight against worldwide pandemic disease COVID-19, cancer and cardiovascular diseases [15–17]. The theory of medicine and food homology originated from ancient times and developed for thousands of years in China [18]. MEPs come from nature, and could be employed for disease treatment and healthcare [19]. These plants have unique pharmacological characteristics and chemical structures, and the containing bioactive components are extraordinary sources of drug discovery [20–22]. Simultaneously, these substances can be made into various diets or food stuff, which are widely consumed in daily life [23]. Compared to the lipid-lowering drugs with many adverse effects, MEPs exhibit great advantages such as high efficiency, good tolerance and commercial value. In recent years, although reviews on the treatment of dyslipidemia with TCM formulas, natural products and dietary supplements have been reported [24–28], the review of herbal medicines with food properties is still rare. In this article, we will introduce 20 kinds of MEPs commonly used in clinic and daily life with lipid-lowering effects in the aspects of source, efficacy, target and underlying mechanism, which may provide inspiration for the development of new drugs, functional foods and complementary therapy.

Methodology and strategy

This review focused on experimental studies in vivo and in vitro. Primarily, MEPs were selected with reference to the Catalogue of Food and Chinese Medicine Homologous substances issued by the National Health Commission of China [29, 30], Interpretation of Food and Chinese Medicine Homologous Substances [31], and Chinese Pharmacopoeia (2020 edition) [32]. Secondly, according to the reference books and China National Knowledge Infrastructure (CNKI) database, the professional names, common names, and main bioactive components of the plants were collected. Further, publications about the MEPs were searched in PubMed, Web of Science, Google Scholar, and CNKI using relevant medical subject headings (MeSH) and keywords, including the names and active components of the plants, "dyslipidemia", "hyperlipidemia", "cholesterol", "triglyceride", and "lipid metabolism". Finally, the relevant experimental studies in the past five years (from January 1, 2017 to January 1, 2022) were retrieved.

MEPs for treating dyslipidemia

We found that many kinds of MEPs, including the parts of barks, flowers, fruits, leaves, peels, rhizomes, roots, seeds, and the whole herbs, have lipid-lowering effects (Fig. 1). Next, we will introduce these plants in detail.

Barks

*Cinnamomi cortex (Rougui)*

*Cinnamomi cortex*, commonly known as cinnamon, is the dried inner bark of *Cinnamomum cassia* Presl of the family Lauraceae [31, 32]. It is one of the essential spices traditionally used to flavor foods in African, Asian and European countries, as well as a folk herbal medicine to treat diseases [33]. There are two main types of cinnamon namely Ceylon cinnamon (*Cinnamon zeylanicum* Blume) and Chinese Cassia.*

![Fig. 1 Schematic diagram of the effects and mechanisms of MEPs in modifying dyslipidemia. HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; MEPs, medicinal and edible plants; TC, total cholesterol; TG, triglyceride; VLDL, very low-density lipoprotein](image-url)
(Cinnamomum aromaticum Ness) [34]. The former grows in Sri Lanka and southern India, and the latter grows in China, Indonesia and Vietnam [35]. Studies have revealed that cinnamon contains chemical components such as cinnamic acid, linoleic acid, oleic acid, essential oil, eugenol, diisobutyl phthalate, and cinnamaldehyde [36]. These bioactive ingredients endow it with antioxidant, anti-inflammatory, antibacterial, antifungal, anticancer and anti-diabetic pharmacological effects [37]. Most importantly, cinnamon and its polyphenolic compounds have therapeutic effects on dyslipidemia.

In hyperlipidemia albino rats, after supplementation of cinnamon powder (4 g/kg body weight) for 30 days, the total cholesterol (TC), triglyceride (TG) and low-density lipoprotein cholesterol (LDL-C) levels in serum significantly decreased, whereas the concentration of high-density lipoprotein cholesterol (HDL-C) elevated [38]. Apart from regulating lipid particles, cinnamon also showed great potential in treating metabolic diseases associated with dyslipidemia. In obese mice treated with a high-fat diet and 1% cinnamon extracts for 14 weeks, the body weight gain as well as the serum TC and TG were significantly reduced compared to the control [39]. Long-term high-fat dietary intake not only leads to dyslipidemia and weight gain, but also causes abnormal blood sugar and insulin resistance. Cinnamon polyphenol (100 mg/kg) administered for 12 weeks can decrease serum lipid profiles and glucose of rats fed with high-fat diet, alleviate inflammatory response and inhibit oxidative stress. The underlying mechanism is associated with the activation of transcription factors and antioxidative defense target genes mediated by sterol regulatory element-binding protein (SREBP) 1c, liver X receptor α (LXRα), peroxisome proliferator-activated receptors α (PPARα), NF-κB and Nrf2 signaling pathway [40].

In addition to Chinese cassia, other varieties of cinnamon have also been found to improve lipid metabolism. In hypercholesterolemia mice model induced by quail yolk, TC content in serum decreased after administration of cinnamon (Cinnamomum burmanii) for 28 days [41]. Similarly, cinnamon (Cinnamomum zeylanicum) bark extract supplement can reduce the blood levels of TC and TG in hyperlipidemia albino rats induced by Triton X-100 injection [42]. In vitro, cinnamate in Ceylon cinnamon showed inhibitory activity of 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase. Phenolic compounds such as gallic acid, catechin, and epicatechin might decrease cholesterol synthesis and absorption by inhibiting pancreatic lipase, cholesterol esterase, and cholesterol micellization [43].

Flowers

Chrysanthemi flos (Juhua)

Chrysanthemi flos (chrysanthemum) is the dried flower head of Chrysanthemum morifolium Ramat. of Compositae [31, 32]. It is famous as a beautiful ornamental plant, which has been used for horticulture, decoration, cut flowers, garland making, and religious ceremonies in many countries [44]. Chrysanthemum originated in China and has traditionally served as flower tea for healthcare and herbal medicine to treat diseases for more than 3000 years [45]. According to different origins and processing methods, it can be classified into four types, including "Boju", "Chuju", "Gongju" and "Hangju" [31]. Many phenolic compounds beneficial to human health have been found in chrysanthemum [46], such as caffeoylquinic acids, phenolic acids and flavonoids [47, 48]. Attributing to these bioactive ingredients, chrysanthemum possesses effects of antioxidation, anti-inflammation, antiobesity, and hypolipidemia [49].

Hangju is one of the most popular high-quality chrysanthemums both for tea and medicine in China. The 0.2% and 0.4% Hangju extract can attenuate the serum lipid concentrations, weight gain and inflammatory response of obese rats induced by a high-fat diet. The underlying mechanism is to activate adenosine monophosphate-activated protein kinase (AMPK) signaling pathway, suppress lipid synthesis gene expression and adipogenesis-related enzyme activity in white adipose tissue and liver, as well as increase gene expression involved in fatty acid oxidation [50]. Another study indicated that Hangju extract (1, 2 or 4 g crude drugs/kg/d) administration for 8 weeks can reduce the levels of TC, TG, LDL-C and LDL/HDL in serum of hyperlipidemia rats, increase serum HDL-C level, and alleviate oxidative damage induced by oxidized LDL (ox-LDL) in vitro [51]. Chrysanthemum has pleasing appearance and phytopharmacological activities attributed to its various flavonoids, such as luteolin, apigenin, acacetin, diosmetin and their glycoside derivatives [47, 52]. These compounds might be the bioactive components for lipid-lowering. Luteolin (50 mg/kg-bw/d) and luteoloside (25 mg/kg-bw/d) in chrysanthemum given for 6 weeks were reported to improve serum lipid profiles of TC, TG, LDL-C and apolipoprotein B (ApoB). It can modulate the enzymes activities of fatty acid β-oxidase (FaBO), cholesterol 7 alpha-hydroxylase (CYP7A1), liver lipase (HL) and diacylglycerol acyltransferase (DGAT) to promote the fatty acid activation and β-oxidation, cholesterol conversion to bile acids and triglyceride metabolism. Meanwhile, fatty acid and cholesterol synthesis were decreased by inhibiting the activities of fatty acid synthase (FAS) and HMG-CoA [53].
**Fruits**

*Citrus sarcodactylis fructus* (Foshou)

*Citrus sarcodactylis fructus*, commonly known as bergamot, is the dried fruit of *Citrus Medica L. var. Sarcodactylis* Swingle of family Rutaceae [31, 32]. Bergamot is native to Calabria in southern Italy, and is used to treat or cure various symptoms, including fever, sore throat and vomiting, cough and excessive phlegm [32]. It can be processed into edible preserved fruits and is widely used in the folks to promote digestion, improve appetite, and resolve phlegm [56]. Bergamot contains flavonoids, coumarins, volatile oil, polysaccharides, amino acids, inorganic elements and other bioactive chemical components [57]. It exerts a high antioxidant and selective antibacterial activity, growth stimulation on gut-beneficial bacteria and protective effect on human microvascular endothelial cells [58]. Notably, evidence has accumulated that bergamot has hypolipemic activity and hepatoprotective effects [59].

Bergamot extract (0.85 and 0.56 mg/ml) was reported to reduce the cholesterol content, lipid droplet accumulation and reactive oxygen species levels in murine pre-adipocytes 3T3-L1 cells [60]. The lipid-lowering mechanism is related to the inhibition of hydroxymethyl glutaryl-CoA reductase (HMGR) and membrane transporters Niemann-Pick C1 Like 1 (NPC1L1), which leading to the reduction of cholesterol biosynthesis and absorption [61].

Natural bergamot polyphenolic fraction contains more than 40% of flavonoids, such as neoevoricitrin, naringin, neohesperidin and bruteridin [62], which might be the effective components for dyslipidemia and nonalcoholic steatohepatitis. Studies found that bergamot polyphenolic fraction (50 mg/kg/d) administered for 11 weeks can reduce the levels of TG, LDL-C and glucose in blood of mice, alleviate oxidative stress reaction, and improve the key histological and pathophysiological characteristics of nonalcoholic steatohepatitis induced by a high-fat diet and sugar water [63]. In the hyperlipidemic rat model, bergamot polyphenolic fraction (20 mg/kg/d) supplementation for 90 days has been proved to decrease serum TC, TG, LDL-C and fasting plasma glucose whereas increase HDL-C. The underlying mechanism is to regulate the activity of lipid transfer proteins, including acetyl-CoA acetyltransferase (ACAT), lecithin cholesterol acyltransferase (LCAT), and cholesteryl ester transfer protein (CETP) [64]. In addition, cholesterol absorption can be decreased by inhibiting the activity of pancreatic cholesterol ester hydrolase (pCEH) [65].

Naringin, a flavanone-7-O-glycoside contained in bergamot, can reduce the levels of TC, TG and LDL-C by activating AMPK and downregulating the gene expression of SREBP-1 and SREBP-2. Meanwhile, it can decrease and increase the expression of PCSK9 and low-density lipoprotein receptor (LDLR), respectively, to facilitate cholesterol uptake and degradation [66].

**Crataegus fructus** (Shanzha)

*Crataegus fructus*, also known as hawthorn, is the dried mature fruit of *Crataegus pinnatifida* Bge. var. Major N.E.Br. or *C. pinnatifida* Bge. of family Rosaceae [31, 32]. Hawthorn is a red berry that can be made into juices and snacks with sugar or honey, and is recognized to promote digestion. Hawthorn has been used extensively in folk medicine and food production for centuries [67]. It contains flavonoids, organic acids, triterpenoids, polysaccharides and other chemical components [68]. Studies have reported that hawthorn exerts pharmacological effects such as hypolipidemia, lowering blood pressure, hypoglycemia, anti-inflammation, antioxidant, and anti-atherosclerosis [69, 70].

The ethanol extract of hawthorn contains chemical components including chlorogenic acid, hypericin, isoquercitrin, rutin, quercetin, vitexin and apigenin. It can reduce the lipid contents in serum and modulate the perturbed metabolism pathways induced by a high-fat diet in vivo, and inhibit differentiation and TG accumulation in a dose-dependent manner in vitro [71, 72]. Moreover, hawthorn extract and its polysaccharide can lower blood lipids and glucose by inhibiting alpha-glucosidase and pancreatic lipase [73, 74]. In hyperlipidemia mice, freeze-dried hawthorn powder (1, 2.5 g/kg) administration for 12 weeks improved the lipid disorders induced by a high-fat. It can increase the abundance of intestinal flora and restore the composition of intestinal microbes [75]. In addition, supplemented with hawthorn concentrated juice (10, 15, 20 ml/kg) for 5 weeks, the contents of TC, TG, LDL-C, and very low-density lipoprotein cholesterol (VLDL-C) in serum decreased, while the HDL-C level increased. The improvement of LCAT activity and oxidative stress response may be involved in the regulation of lipid metabolism [76].

Haw pectin penta-oligogalacturonide (300 mg/kg) purified from hawthorn pectin hydrolysates can down-regulate the mRNA and protein expression of farnesoid X receptor (FXR) and increase CYP7A1 and apical sodium-dependent bile acid transporter (ASBT) in the small intestine of mice, thereby inhibiting intestinal bile acids reabsorption, promoting hepatic bile acids biosynthesis, and improving cholesterol metabolism [77]. Hawthorn crude glycoprotein has good lipid-lowering effects and antioxidant activities. It can reduce TC and TG levels, and increase HDL-C content [78]. Vitexin, a flavonoid extracted from hawthorn, can decrease serum
lipid profiles, blood glucose and adipogenesis by activating AMPKα and inhibiting the expression of downstream proteins CCAAT/enhancer binding protein α (C/EBPa) and FAS [79]. Intriguingly, hawthorn can not only ameliorate blood lipid metabolism, but also inhibit the formation of foam cells, resist the inflammatory reaction and regulate gut microbiota, which has potential anti-atherosclerosis effects [80].

**Gardenia fructus** (Zhízī)

*Gardenia fructus*, the dried ripe fruit of evergreen shrub *Gardenia jasminoides* Ellis of family Rubiaceae, is mainly distributed in tropical and subtropical regions of the world. It has been traditionally used as an edible and medicinal substance for centuries in China [81]. Coincidentally, another species named *Gardenia resinafera* Roth., mainly grown in the Indian peninsula, Bangladesh and Myanmar, is an excellent crude drug in Indian medicine [82]. *Gardenia fructus* contains multiple chemical components, such as iridoids, iridoid glycosides, flavonoids, gardenia yellow pigment, triterpenoids, organic acids, and volatile oil. Among them, geniposide, genipin, gardenoside, iridoid and crocin play essential pharmacological active roles [81, 83]. Studies reported that *Gardenia fructus* can be used for treating diabetes, depression, Alzheimer’s disease and Parkinson’s disease [84–86]. Recently, its potential therapeutic effects on hyperlipidemia, anti-oxidative stress and anti-atherosclerosis have received much attention.

Research showed that after *Gardenia fructus* extract (25, 50, and 100 mg/kg) administration for 6 weeks, the serum TC, LDL-C, and TG levels of rats decreased in a dose-dependent manner. The potential mechanism is to regulate the mRNA expression of lipogenesis, including SREBP-1c, FAS, stearoyl-CoA desaturase 1 (SCD1), PPARα, and carnitine palmitoyltransferase 1 (CPT1) [87].

Geniposide, a well-known iridoid glycoside isolated from *Gardenia fructus*, can decrease the serum TC, TG, LDL-C, VLDL and ApoC3 contents whereas increase HDL-C. It can enhance the phosphorylation of AMPK, increase the protein level of PPARα and decrease SREBP-1c. Meanwhile, lipid accumulation and oxidative stress damage due to non-alcohol fatty liver (NAFLD) wereameliorated via Nrf2/AMPK/mTOR signaling pathways [88]. In atherosclerosis mice model induced by high fat/cholesterol diet, geniposide expedited reversal cholesterol transport, motivated bile acid synthesis and excretion, and attenuated atherosclerosis inflammatory injury by modulating FXR-mediated bile acids liver-gut cross-talk and miR-101/MKP-1/p38 signaling pathways [89, 90]. Geniposide can also inhibit the phosphorylation of p38MAPK and AKT to regulate the expression of downstream genes and proteins, thereby decrease cholesterol uptake, promote cholesterol efflux, inhibit the formation of foam cells and alleviate the progress of atherosclerosis [91].

Genipin, the primary metabolite and aglycon of geniposide [92], can promote lipolysis and accelerate liver fatty acid β-oxidation via upregulating the gene expressions of hormone-sensitive lipase (HSL), adipose triglyceride lipase (ATGL), CPT1A, and PPARα. As a result, the lipid profiles, body weight, fat accumulation, and insulin resistance decreased [93]. Moreover, genipin inhibits lipid metabolic genes and proteins expression of SREBP-1c, FAS, and SCD1 dose-dependently by regulating miR-142a-5p/SREBP-1c axis, which was verified in vitro as well [94].

**Hippophae fructus** (Shājī)

*Hippophae fructus* (sea buckthorn), the dried ripe fruit of *Hippophae rhamnoides* L. of family Elaeagnaceae, is widely distributed in China, Russia, Mongolia and most parts of Northern Europe. It has been used for food and pharmaceutical purposes in both Europe and Asia for centuries [95, 96]. Currently, sea buckthorn is extensively applied in food, health care, cosmetics, medicines, and many other fields, and has been made into more than 200 kinds of products such as tea, candies, fruit wine, yogurts, seasoning, freeze-dried fruit powder, and toiletries [96]. According to the report, there are 106 nutrients and 74 bioactive compounds in sea buckthorn, including carbohydrates, proteins, unsaturated fatty acids, vitamins, minerals, polysaccharides, sterols, total triterpenic acids, phenolic acids, flavonoids and so on [97]. Among them, flavonoids and sterols are the main pharmacologically active components in the treatment of dyslipidemia.

Flavonoids in sea buckthorn have shown potential cardiovascular benefits [98], and play an important role in regulating lipid metabolism [99]. Its administration (100, 200, and 400 mg/kg) for 42 days can reduce the contents of TC, TG, and LDL-C in serum of hyperlipidemia mice fed with a high-fat diet, and increase HDL-C levels. Moreover, there is no adverse impact on heart, liver, spleen and kidney [100]. Studies also found that the mRNA expressions of PPARα, LXRα, ATP binding cassette subfamily A member 1 (ABCA1) and CPT1A increased, while SREBP-2 and its target gene LDLR decreased after sea buckthorn flavonoids treatment [101, 102]. The lipid-lowering effects is achieved by promoting the conversion of cholesterol into bile acids, inhibiting cholesterol de novo synthesis, and accelerating fatty acid oxidation.

Isorhamnetin, quercetin, and kaempferol are important flavonoid compounds in sea buckthorn. Isorhamnetin can increase the protein expression of LXRα and CYP7A1 [102]. Kaempferol and kaempferide have been
verified to decrease lipid droplets accumulation and TG levels by down-regulating the expression of lipogenesis-related proteins, including SREBP-1, FAS and SCD1. Meanwhile, the expression of two adipogenic transcription factors PPARγ and C/EBPβ were inhibited [103].

Sterols (100, 200, and 400 mg/kg) in sea buckthorn, mainly include campesterol, stigmasteradienol, sitosterol, stigmastanol and a-Amyrin, were reported to lower the contents of TC, TG, LDL-C and ApoB in blood after treatment for 42 days. It can increase the concentrations of HL, lipoprotein lipase (LPL) and ApoA in serum of hyperlipidemia rats, thus promoting lipid transport, metabolism and decomposition [104]. Figure 2 shows the lipid-lowering target genes as well as upstream and downstream signaling pathways of sea buckthorn and other MEPs.

Mori fructus (Sangshen)

*Mori fructus*, commonly known as mulberry fruit, is the dry ear of *Morus alba* L. of the family Moraceae [31, 32]. It is widely cultivated in Asia, Africa, Europe, North and South America [105], and has been traditionally consumed as medicine and food for a long time [106]. Ripe fresh mulberry fruit is sweet and juicy, which can be eaten raw or processed into juice, jams, preserved fruit and wine [107]. Mulberry fruit is rich in fatty acids, amino acids, vitamins, minerals and other nutrients. It contains phytochemical compounds such as anthocyanins, rutin, quercetin, chlorogenic acid, polysaccharides, polyphenols and alkaloids [108, 109]. Attributing to these bioactive ingredients, mulberry fruit has pharmacological effects including hypolipidemia, hypoglycemia, antioxidation, hepatoprotection, and anti-atherosclerosis [108, 109].

In rats fed with a high cholesterol/cholic acid diet for 4 weeks, lipid profiles in the liver and serum showed an increased tendency. However, the levels of TG, TC and LDL-C in blood of rats administered with mulberry fruit extract (4 g/kg) decreased significantly compared with the control group, while the contents of HDL-C in blood...
as well as TC, TG and total bile acids in feces increased. These effects were achieved by regulating the expression of mRNA involved in de novo cholesterol biosynthesis, cholesterol efflux, bile acid synthesis and HDL-C formation [110]. In 3T3-L1 cells, incubation with mulberry fruit extract could activate AMPK and inhibit adipogenesis genes, leading to the decrease of intercellular lipid accumulation and TG content [111].

Fresh mulberry fruit is perishable, while freeze-drying mulberry can be stored for a long time and also has effects of improving lipid profiles. It has been reported that lyophilized mulberries can reduce the body weight gain, visceral fat, plasma glucose and TG of hyperlipidemia mice, and at the same time elevate HDL-C contents. Furthermore, the hepatic lipid accumulation, arterial and cardiac wall hypertrophy as well as aortic collagen fiber accumulation attenuated after mulberry fruit (100 and 300 mg/kg) treatment for 3 months [112].

Polysaccharides isolated from mulberry fruit consists of arabinose, galactose, glucose, rhamnose and galacturonic acid. It can improve dyslipidemia, hyperglycemia, oxidative stress and organ damage by regulating gut microbiota [113]. In diabetic rats induced by a high-fat diet and low dose injection of streptozotocin, mulberry fruit polysaccharides (400 mg/kg) treatment for 7 weeks improved lipid profiles, glucose, insulin resistance and hepatic function. Acute toxicity studies revealed that there was no behavioral changes or organic impairment after 1 week administration of mulberry fruit at a dose of 1000 mg/kg [114].

Leaves
Mori folium (Sangye)
Mori folium, commonly known as mulberry leaf, is the dried leaf of Morus alba L. of Moraceae [31, 32]. Given its rich bioactive components and nutritional value, mulberry leaf has been widely used in functional foods such as herbal teas, beverages, and noodles in China, Japan, and Korea [115]. Mulberry leaf possesses biological activities of hypolipidemia, hypoglycemia, antibacterial, anti-atherosclerosis, anti-inflammatory and antioxidation [116, 117]. It has been adopted to treat metabolic disorders such as diabetes, obesity, hypertension, dyslipidemia, and fatty liver disease [118]. These beneficial functions are associated with its chemical constituents, including phenols (flavonoids and chlorogenic acid), alkaloids (1-deoxynojirimycin and fagomine), terpenoids and polysaccharides [119, 120].

Studies have reported that mulberry leaf improved dyslipidemia by promoting cholesterol efflux and bile acid synthesis. In hypercholesterolemia rats, mulberry leaf powder (0.9, 0.6, and 0.3 g/kg) treatment for 5 weeks can increase the levels of total bile acids in feces and HDL-C in blood, reduce the contents of TC and LDL-C, and alleviate hepatocyte lipid degeneration. The potential mechanism is to promote cholesterol and total bile acid excretion mediated by FXR and CYP7A1 pathways [121]. Mulberry leaf extract mainly including phenolic compounds such as quercetin and kaempferol, which can lower the levels of TC, TG and LDL-C in serum by enhancing the mRNA expression of CYP7A1, LXRα, ATP binding cassette subfamily G member 5 (ABCG5) and ABCG8, increasing the AMPK activity and suppressing hepatic miR-33 expression [122, 123]. Furthermore, it can decrease the expressions of liver lipogenesis protein SREBP-1, FAS and 1-acylglycerol-3-phosphate o-acyltransferase (AGPAT), whereas increase lipolysis protein contents of CPT1 and PPARα [116].

Chemical compounds isolated from mulberry leaf have shown hypolipidemic effect as well. In the diabetic mice model, flavonoids were reported to improve the levels of TG, TC, LDL-C, HDL-C and glucose in serum, which might be related to the activation of AMPK and CPT1 [124]. Another study demonstrated that mulberry leaf flavonoids and its active metabolite quercetin could reduce excessive cholesterol accumulation both in vivo and in vitro, and play a role in lowering blood lipid via decreasing the mRNA and protein expression of SREBP-2 and HMGCR [125]. Likewise, mulberry leaf phenolic and fiber mixture exhibited lipid-lowering effects via reducing the mRNA and proteins expression of FAS, C/EBP-α and PPARγ as well as regulating the gut microbiota [126]. In ethanol-induced liver injury mouse model, mulberry leaf extract and its chlorogenic derivatives improved lipid profiles, attenuated hepatic inflammation and decreased lipid accumulation [127]. Polysaccharides extracted from mulberry leaf administered for 8 weeks can reduce the TC, TG and LDL-C contents in serum whereas increase the HDL-C levels by inhibiting pancreatic lipase activity [128].

Nelumbinis folium (Heye)
Nelumbinis folium, also called lotus leaf, is the dried leaf of Nelumbo nucifera Gaertn. of Nymphaeaceae [31, 32]. It is a fragrant Chinese herbal medicine with functions of clearing heat, removing dampness, and raising clearing qi, which has traditionally been used to treat heatstroke, thirst, diarrhea, and fever [129]. Lotus leaf contains alkaloids, flavonoids, polysaccharides, volatile oil and other chemical components, commonly consumed as tea and embraces pharmacological activities of lipid-lowering, anti-obesity, antibacterial and antioxidation [130].

Lipid metabolism disorders and oxidative stress play a key role in the occurrence and development of high-fat diet-induced NAFLD. Lotus leaf powder (600 mg/kg) treated for 18 weeks can modify lipid metabolism...
disorders, reduce oxidative stress and alleviate NAFLD progress. These effects were achieved by downregulating the mRNA levels of cytochrome P450 2E1 (CYP2E1) and SREBP-1c in liver tissue, as well as inhibiting and enhancing the activity of HMG-CoA and LPL, respectively [131].

Nuciferine, an alkaloid extracted from lotus leaf [132], the main bioactive compounds for dyslipidemia treatment, can regulate the gene expression of key enzymes related to the glycerophospholipid, linoleic acid, and alpha-linolenic acid metabolism pathways in the liver to treat dyslipidemia and NAFLD [133]. Furthermore, it can downregulate the expression of SREBP-1, acetyl-CoA carboxylase (ACC), ATP-citrate lyase (ACLY), and FAS, decrease the levels of TC and TG, and ameliorate liver steatosis [134].

The imbalance of gut microbiota is closely related to the pathogenesis of metabolic diseases, including hyperlipidemia and obesity [135]. Studies have shown that nuciferine can regulate the composition and potential function of intestinal microflora and reduce intestinal permeability, which can prevent weight gain, decrease fat accumulation, and ameliorate lipid metabolism disorders [136, 137]. In vitro, nuciferine can decrease the intracellular TG content and inhibit the proliferation, differentiation, lipid accumulation and adipogenesis of 3T3-L1 preadipocytes. The lipid metabolism related genes PPARγ, SREBP-1, C/EBPα, C/EBPβ, FAS, ACC, and ATGL were involved in this metabolic regulation [138]. Besides, nuciferine contributes to attenuating foam cell formation and atherosclerosis. It can reduce the lipid deposition and TC content of macrophages-derived foam cells via modulating PI3K/AKT/mTOR and PPARγ/LXRα/ABCA1 pathways in a dose- and time-dependent manner [139, 140]. Table 1 summarized the bioactive components, effects, and mechanisms of lotus leaf and other MEPs on dyslipidemia treatment.

**Peels**

*Citri reticulatae pericarpium* (Chenpi)

*Citri reticulatae pericarpium* (Chenpi) is the dried mature peel of *Citrus reticulata* Blanco and its cultivars [31, 32]. Chenpi can be made into snack foods, beverages, tea, or used as cooking materials, seasonings, and spices [141]. It has pharmacological activities of promoting digestion, protecting the liver, anti-asthma, anti-cough, anti-inflammation, and anti-oxidation [142]. Approximately 140 chemical constituents have been separated and identified from Chenpi, and the main bioactive components are flavonoids, limonoids, alkaloids, and volatile oils [141, 143].

Flavonoids in Chenpi are mainly divided into flavonoid glycosides (hesperidin, naringin, etc.) and polymethoxyflavonoids (nobiletin, tangeretin, etc.) [144]. Polymethoxyflavonoids is the unique chemical composition of citrus. It is a low polarity fat-soluble substance, easily soluble in organic solvents such as hot ethanol and ethyl acetate, but hardly dissolves in water [145]. Studies have reported that Chenpi extracts, especially extracted with 95% ethanol and ethyl acetate, can significantly reduce the TC and LDL-C levels in serum of hyperlipidemia rats induced by fat emulsion. Pharmacodynamics-component correlation analysis showed that polymethoxyflavonoids might be the effective component in lowering blood lipids [146]. HMGCR is the rate-limiting enzyme of cholesterol biosynthesis [147]. The 95% ethanol extract of Chenpi can decrease the contents of TC and LDL-C by inhibiting the activity of HMGCR and regulating ApoB and ApoA1 [148]. It can also reduce the serum levels of TG and free fatty acids (FFA) via increasing the activity of triglyceride metabolic related enzymes ATGL, LPL and HL, and up-regulating the mRNA expressions of PPARγ and FXR [149]. Moreover, water extract of Chenpi can modulate the abundance and diversity of gut microbiota to improve serum lipid parameters and decrease body weight [150].

**Zanthoxyli pericarpium** (Huajiao)

*Zanthoxylum pericarpium* is the dried pericarp of *Zanthoxylum schinifolium* Sieb. et Zucc. or *Z. bungeanum* Maxim. of family Rutaceae [31, 32]. There are many varieties of *Zanthoxylum Pericarpium* for both medicinal and edible purposes. In various parts of Asia, Africa and America, *Z. bungeanum* specie is used by locals in food preparation and as a raw medicinal material [151]. In China, Szechuan pepper is a popular variety commonly used in daily cooking due to its exceptional aroma and flavor [152]. The narcotic or anti-irritant properties render them effective for pain relief, especially in the treatment of toothache [153]. *Zanthoxylum pericarpium* contains chemical components including volatile oil, alkaloids, amides, coumarin, lignin, fatty acids, triterpene and sterols [154], which endows it with biological activities of antioxidation, anti-inflammation, antitumor, antibacterial, gastrointestinal system regulation, and hypolipidemia [155, 156].

Hydroxy-a-sanshool isolated from *Z. bungeanum* has been found to exert lipid-lowering and anti-obesity effects in hyperlipidemia rats. After supplementation for 4 weeks, the contents of TC, TG and LDL-C in serum and liver significantly decreased, while HDL-C increased. Furthermore, abdominal adipose tissues, liver adipocytes and levels of oxidative stress markers reduced. The underlying mechanism is to promote lipid metabolism and lipoprotein transformation by up-regulating the expression of PPARγ and ApoE [157].
| No | MEPs                                                                 | Active ingredients                      | Lipid metabolism                | Signaling pathway                                                                 | Mechanism of action                                                                 | References |
|----|----------------------------------------------------------------------|-----------------------------------------|----------------------------------|-----------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|------------|
| 1  | *Cinnamomi cortex*                                                   | Polyphenol                              | ↓TC, TG, LDL; ↑HDL               | 1) Inhibit the expressions of SREBP-1c, ACly, and FAS; 2) Increase the expressions of PPAR-α and IRS | 1) Inhibit triglyceride synthesis; 2) Promote fatty acid oxidation; 3) Increase insulin sensitivity | [40]       |
| 2  | *Chrysanthemi flos*                                                  | Extract                                 | ↓TC, TG, LDL                     | 1) Downregulate PPAR-γ, SREBP-1c, C/EBP-α, CD36, ACly, ACC, FAS, SCID1, and DGAT2; 2) Upregulate PPARα and CPT1α; 3) Activate AMPK signaling pathway | 1) Inhibit triglyceride biosynthesis; 2) Increase fatty acid oxidation             | [50]       |
| 3  | *Citri sarcodactylis fructus*                                         | Extract                                 | ↓TC                              | 1) Activate AMPK phosphorylation; 2) Inhibit the activity of HMG-CoA, HMGCR and NPC1L1; | 1) Inhibit cholesterol biosynthesis; 2) Inhibit cholesterol absorption               | [60, 61]   |
|    |                                                                      | Polyphenols                             | ↓TC, TG, LDL, Apo B; ↑Apo A1      | 1) Inhibit the activity of pCEH, ACAT and CETP; 2) Enhance the activity of LCAT     |                                                                                     |            |
|    |                                                                      | Naringin                                | ↓TC, LDL                         | 1) Upregulate p-AMPKα and LDLR; 2) Downregulate SREBP-1, SREBP-2, and PCSK9        | 1) Inhibit lipids biosynthesis; 2) Promote cholesterol metabolism                   | [66]       |
| 4  | *Crataegi fructus*                                                   | Extract; powder; juice                  | ↓TC, TG, LDL; ↑HDL               | 1) Regulate the perturbed metabolism pathways; 2) Inhibit pancreatic lipase; 3) Increase the LCAT activity | 1) Improve gut microbiota; 2) Inhibit lipid absorption; 3) Promote reverse cholesterol transport | [71, 72, 75, 76, 80] |
|    |                                                                      | Pectin penta-oligogalacturonide         | /                                | 1) Inhibit FXR-FGF15 axis; 2) Increase CYP7A1 and ASBT                           | 1) Promote bile acids biosynthesis; 2) Inhibit intestinal bile acid reabsorption     | [77]       |
|    |                                                                      | Crude glycoprotein                      | ↓TC, TG; ↑HDL                    | /                                                                                | /                                                                                  | [78]       |
|    |                                                                      | Vitexin                                 | ↓TC, TG                          | 1) Activate AMPKα; 2) Downregulate C/EBPα and FAS                                 | Inhibit de novo lipogenesis                                                       | [79]       |
| No | MEPs       | Active ingredients     | Lipid metabolism | Signaling pathway                                                                 | Mechanism of action                                                                 | References |
|----|-----------|------------------------|-------------------|-----------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|------------|
| 5  | Gardeniae fructus Extract | Gardeniae fructus Extract | ↓TC, TG, LDL      | 1) Downregulate SREBP-1c, FAS, SCID1, and PPARγ; 2) Upregulate PPARα and CPT-1      | Inhibit biosynthesis of triglyceride and cholesterol                                 | [87]       |
|    | Geniposide | Geniposide             | ↓TC, TG, LDL, VLDL, ApoC3; ↑HDL | 1) Enhance the phosphorylation of ACC, AMPKα, and AMPKB; 2) Upregulate PPARα, LDLR, SR-B1, ABCA1, ABCG1, CYP7A1, CYP27A1, CYP7B1, and CYP8B1; 3) Downregulate SREBP-1c, miR-101 and SR-A; 4) Inhibit FXR-mediated bile acids liver-gut crosstalk | 1) Inhibit triglyceride and cholesterol biosynthesis; 2) Decrease free cholesterol esterification and cholesterol uptake; 3) Promote cholesterol efflux; 4) Facilitate reverse cholesterol transport; 5) Motivate bile acid biosynthesis and excretion | [88–91] |
|    | Genipin    | Genipin                | ↓TC, TG           | 1) Upregulate the gene expressions of HSL, ATGL, CPT-1α and PPARα; 2) Downregulate SREBP-1c, FAS, and SCID1 | 1) Promote triglyceride decomposition; 2) Inhibit triglyceride synthesis               | [93, 94] |
| 6  | Hippophae fructus Flavonoids; isorhamnetin | Hippophae fructus Flavonoids; isorhamnetin | ↓TG               | 1) Upregulate PPARα, LXRα, LDLR, CYP7A1, ABCA1 and CPT1A; 2) Downregulate SREBP-2 | 1) Promote cholesterol metabolism; 2) Inhibit cholesterol de novo synthesis; 3) Accelerate fatty acid oxidation | [101, 102]|
|    | Kaempferol and kaempferide | Kaempferol and kaempferide | ↓TG               | Downregulate SREBP-1, FAS, SCID1, PPARγ and C/EBPβ                               | Inhibit fatty acid synthesis and adipogenesis                                       | [103] |
|    | Sterols    | Sterols                | ↓TC, TG, LDL; ↑HDL | 1) Increase Apo-A, HL and LPL; 2) Reduce Apo-B                                  | Promote lipids transport and decomposition                                           | [104] |
| 7  | Mori fructus Extract | Mori fructus Extract | ↓TC, TG, LDL; ↑HDL | 1) Downregulate miR-33, miR-21, miR-143, FXR, SREBP-2, PPARγ, and C/EBPα; 2) Upregulate LXR-α, ABCG5, CYP7A1, ABCA1, ApoA-1 and LCAT; 3) Inhibit GPDH activity; 4) Increase AMPK activity | 1) Inhibit de novo cholesterol biosynthesis; 2) Increase bile acids synthesis; 3) Promote cholesterol reversal transport; 4) Inhibit adipogenesis and adipocyte differentiation | [110, 111]|
|    | Polysaccharides | Polysaccharides | ↓TC, TG, LDL; ↑HDL | Selective enrich bacteria and reduce intestinal microbial diversity | Regulate gut microbiota                                                             | [113] |
| No | MEPs                  | Active ingredients | Lipid metabolism | Signaling pathway                                                                 | Mechanism of action                                                                 | References |
|----|----------------------|--------------------|------------------|-----------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|------------|
| 8  | *Mori folium*        | Powder             | ↓TC, LDL; ↑HDL   | 1) Inhibit FXR expression; 2) Promote CYP7A1 expression; 3) Maintain the ratio of ABCGS/ABCG8 | 1) Promote cholesterol efflux; 2) Promote bile acids biosynthesis and excretion       | [121]      |
|    | Extract              | ↓TC, TG, LDL; ↑HDL | 1) Increase CYP7A1, LXRα, ABCGS/ABCG8, CPT1 and PPARα expression; 2) Decrease SREBP-1, FAS, AGPAT and miR-33 expression; 3) Increase the AMPK activity | 1) Increase hepatic bile acid biosynthesis; 2) Inhibit lipid biosynthesis; 3) Promote lipid degradation; 4) Promote fecal cholesterol excretion | [116, 122, 123] |
|    | Flavonoids, quercetin| ↓TC, TG, LDL; ↑HDL | 1) Activate AMPK-PGC-1α signaling pathway; 2) Downregulate SREBP-2, HMGCR, LXRβ and miR-33a; 3) Increase the expressions of CPT-1 and CYP7A1 | 1) Promote mitochondrial fatty acid oxidation; 2) Improve insulin resistance; 3) Inhibit cholesterol biosynthesis; 4) Promote cholesterol convert to bile acid; | [124, 125] |
|    | Polyphenols and fiber| ↓TC, TG, LDL; ↑HDL | 1) Downregulate FAS, C/EBP-α and PPARγ; 2) Improve intestinal flora diversity | 1) Inhibit triglyceride biosynthesis and adipocyte differentiation; 2) Regulate gut microbiota | [126]      |
|    | Polysaccharides      | ↓TC, TG, LDL; ↑HDL | Inhibit pancreatic lipase activity | Inhibit lipids absorption | [128]      |
| 9  | *Nelumbinis folium*  | Powder             | ↓TC, TG          | 1) Downregulate SREBP-1c mRNA; 2) Inhibit HMG-CoA activity; 3) Enhance LPL activity | 1) Inhibit synthesis of triglycerides and cholesterol; 2) Promote triglyceride decomposition | [131]      |
|    | Nuciferine           | ↓TC, TG, LDL       | 1) Downregulate SREBP-1, ACLY, ACC, FAS, PPARγ, C/EBPα and C/EBPβ; 2) Upregulate LCAT activity and PPARγ/LXRα/ABCA1 pathways; 3) Inhibit PI3K/AKT/mTOR pathways; 4) Alter the diversity and composition of gut microbiota | 1) Inhibit lipids biosynthesis; 2) Increase cholesterol efflux; 3) Promote autophagy and reduce macrophage foaming; 4) Regulate gut microbiota | [133, 134, 136–140] |
| 10 | *Citri reticulatae pericarpium* | Ethanol extract | ↓TC, TG, LDL, ApoB, ↑ApoA1 | 1) Inhibit the activity of HMGCR; 2) Regulate apolipoprotein; 3) Regulate PPARγ-LPL/ATGL/HSL and FXR-HL pathway | 1) Decrease cholesterol synthesis; 2) Regulate cholesterol transport; 3) promote triglyceride metabolism | [148, 149] |
|    | Water extract        | ↓TC, TG, LDL; ↑HDL | Alter the diversity and composition of gut microbiota | Improve gut microflora | [150]      |
| 11 | *Zanthoxyli pericarpium* | Hydroxy-α-sanshool | ↓TC, TG, LDL; ↑HDL | Increase mRNA and protein expression of PPARγ and ApoE | Promote lipid metabolism and lipoprotein transformation | [157]      |
| No | MEPs | Active ingredients | Lipid metabolism | Signaling pathway | Mechanism of action | References |
|----|------|---------------------|------------------|------------------|---------------------|------------|
| 12 | Dioscoreae rhizoma | Diosgenin | ↓ TC, TG; ↑ HDL | Activate the catabolic pathway via AMPK | Inhibit cholesterol absorption and facilitate cholesterol excretion | [162] |
|    | Resistant starch | | ↓ TC, TG, LDL; ↑ HDL | Increase the relative abundance of probiotics | Regulate gut microbiota | [164] |
| 13 | Polygonati rhizoma | Extract | ↓ TC, LDL; ↑ HDL | 1) Upregulate CPT-1 mRNA expression; 2) Regulate the composition and concentration of amino acids, carbohydrates and esters | 1) Promote fatty acid β-oxidation; 2) Regulate endogenous metabolites | [165, 170] |
|    | Polysaccharides | | ↓ TC, TG, LDL; ↑ HDL | 1) Upregulate PPAR-α and PPAR-β; 2) Downregulate PPAR-γ and SREBP-1c; 3) Regulate gut microbiota and restore the intestinal permeability barrier; | 1) Inhibit lipid synthesis; 2) Promote fatty acid oxidation and lipolysis; 3) Regulate gut microbiota | [171, 172] |
|    | Saponin | | ↓ TC, TG, LDL; ↑ HDL | Modulate the composition, abundance and diversity of gut microbiota | Regulate gut microbiota | [173] |
|    | Syringaresinol-di-O-β-D-glucoside | | ↓ TC, TG, LDL-C, VLDL-C, FFA | Promote insulin secretion | Improve insulin sensitivity | [174] |
| 14 | Astragali radix | Total flavonoids | ↓ TC, TG, LDL; ↑ HDL | 1) Upregulate FXR, TGR5, CYP7A1, ASBT, AMPKa and CPT1α; 2) Downregulate FAS and SREBP-1c; | 1) Promote bile acids synthesis and excretion; 2) Enhance fatty acid oxidation; 3) Inhibit lipid synthesis | [182, 183] |
|    | Astragaloside IV | | ↓ TC, TG, FFA; ↑ HDL | 1) Activate AMPK, ACC and SREBP-1 phosphorylation; 2) Downregulate SREBP-1, ACC1, FAS and SCD1 | Inhibit lipid biosynthesis | [185, 186] |
| 15 | Puerariae radix | Extract | ↓ TC; ↑ HDL | Activate AMPK and PGC-1α proteins | Promote mitochondrial biogenesis and energy metabolism | [193] |
|    | Puerarin | | ↓ TC, TG, LDL | 1) Downregulate SREBP-1c, FAS, SCD1 and HMGCR; 2) Upregulate CPT1, ACOX and H; 3) Increase the phosphorylation of AMPK and ACC | 1) Inhibit triglycerides and cholesterol synthesis; 2) Promote fatty acid oxidation and lipolysis | [194, 195] |
|    | Polysaccharides | | ↓ TC, TG, LDL, FFA; ↑ HDL | 1) Downregulate SREBP-1 and ACC; 2) Upregulate PPARα and LDLR; 3) Upregulate FXR, FGFR4, CYP7A1, BSEP, MRP2, and LXR | 1) Inhibit lipid synthesis; 2) Promote β-oxidation; 3) Promote LDL-C degradation; 4) Promote bile acids synthesis and excretion | [187, 196] |
Rhizomes
Dioscoreae rhizoma (Shanyao)

Dioscoreae rhizoma, also known as Chinese yam, is the dried rhizome of Dioscorea opposita Thunb. of Dioscoreaceae [31, 32]. The roots, tubers, and rhizomes of yam have been used as food and traditional medicine by indigenous people since pre-historic times [158]. In West Africa and Asia, yam tubers are usually boiled, fried, baked, roasted, or eaten raw [158]. Yam provides abundant nutritional benefits and contains plentiful chemical compounds including diosgenin, flavonoids, polysaccharides, phenols, saponins, tannins and alkaloids [159]. Studies suggest that yam possesses potential pharmacological activities such as lipid-lowering, immunomodulation, antioxidation, estrogen stimulation, angiotensin I-converting enzyme inhibition and trypsin inhibition [160].

Diosgenin, a steroid sapogenin isolated from yam, is considered as a natural precursor of steroidal drugs [161]. In Wistar rats fed with high-cholesterol diets, administration of 0.5% diosgenin for 6 weeks significantly increased serum HDL concentrations and fecal cholesterol contents, but decreased the levels of hepatic TC, TG and fecal bile acids. The potential lipid-lowering mechanism might be through activating the catabolic pathway of AMPK, thus inhibiting cholesterol absorption and facilitating cholesterol excretion [162]. Resistant starch is a component of starch that is not digested in the small intestine but fermented by the microbiota in colon and produces short-chain fatty acids [163].
golden hamsters induced by a high-fat diet, supplementation of resistant starch (0.5 and 1.5 g/100 g) obtained from yam for 4 weeks significantly improved blood lipid profiles, including TC, TG, LDL-C and HDL-C, which was achieved by increasing the alpha diversity of gut microbiota (Table 1 and 2) [164].

Polygonti rhizoma (Huangjing)

*Polygonti rhizoma* is the dried rhizome of *Polygonatum kingianum* coll. et Hemsl, *P. sibiricum* Red. or *P. cyrtonema* Hu of family Liliaceae [32]. In Asia, Europe and North America, it has traditionally been used as herbal medicine and nutrient food to treat diabetes, cough, fatigue and feebleness [165, 166]. *Polygonti rhizoma* contains many chemical ingredients, mainly including polysaccharides, steroidal saponins, flavonoids, alkaloids, lignin and amino acids [167]. Attributed to these compounds, *Polygonti rhizoma* has pharmacological effects of anti-aging, anti-tumor, immunomodulation, antibacterial, hypoglycemic and hypolipidemia [168, 169].

High-fat diet leads to NAFLD, administration of *Polygonti rhizoma* extract (4 g/kg) for 14 weeks restored disordered blood lipid levels of rats, including TC, LDL-C and HDL-C. It can upregulate and downregulate the mRNA expression of CPT1 and uncoupling protein 2 (UCP2), respectively, as well as modulate endogenous metabolites [165, 170]. Meanwhile, NAFLD was ameliorated due to the enhancement of mitochondrial antioxidant function and fatty acid β-oxidation [165].

Polysaccharides and saponins are likely to be the effective compounds for dyslipidemia treatment. In hyperlipidemia mouse model induced by intraperitoneal injection of 75% fresh egg yolk emulsion, *Polygonti rhizoma* polysaccharides can reduce the contents of TC, TG, and LDL-C in serum whereas increase HDL-C. Its lipid-lowering mechanism is related to modulating the mRNA and protein expressions of PPARs and SREBP-1c [171]. Besides lipidemia, other metabolic diseases such as diabetes and obesity can also be ameliorated by *Polygonti rhizoma*. The polysaccharides (120, 240 and 480 mg/kg) treatment for 14 weeks can reduce the levels of blood lipids, glucose and weight gain by acting on the intestinal flora. It can regulate the composition, abundance and diversity of gut microbiota, decrease intestinal epithelial cell permeability and inhibit lipase entry into the entero-hepatic circulation [172].

Saponin, the essential active component of *Polygonti rhizoma*, was found to decrease serum lipid profiles and glucose in type 2 diabetes mellitus (T2DM) mice induced by a high-fat diet and streptozotocin solution injection. Further analysis suggested that the improvement of the gut microbiota might be responsible for the restoration of metabolic disorders [173]. Syringaresinol-di-O-β-D-glucoside, a phenolic compound isolated from *Polygonti rhizoma*, is able to lower the levels of TC, TG, LDL-C, VLDL-C and FFA in serum of diabetic mice, decrease the levels of oxidative stress indexes and increase insulin sensitivity [174].

Roots

*Astragali radix* (Huangqi)

*Astragali radix* is the dried root of *Astragalus membranaceus* (Fisch.) Bge. var. *mongolicus* (Bge.) Hsiao or *Astragalus membranaceus* (Fisch.) Bge. of family Leguminosae [31, 32]. Northern China and Mongolia are the origins of *Astragali radix*, which is also cultivated in other temperate regions of the world such as Siberia and North Korea [175]. Due to its pharmacological activity, it is commonly used as a crude drug in Oriental medicine [176]. For example, *Astragali radix* is a popular tonic herb for nourishing qi and blood, as well as promoting urination to relieve edema in TCM [177]. In addition to medicinal uses, it can also be made into herbal tea, beverages, and cooking dishes for daily consumption [178]. There are more than 100 compounds identified from *Astragali radix*, including saponins (astragaloside, acetystraigaloside, isoastragaloside, etc.), flavonoids (Calycosin 7-O-glucoside, kaempferol, quercetin, isorhamnetin, etc.), polysaccharides, amino acids and trace elements [179, 180]. Studies indicate that *Astragali radix* has pharmacological effects of anti-oxidation, hypolipidemia, hypotension, anti-inflammation, immune regulation, cardiovascular protection and anti-hepatic fibrosis [175, 179, 181].

It was found that flavones derived from *Astragali radix* could reduce the levels of cholesterol and triglyceride, while increasing the content of HDL-C both in vivo and in vitro. This beneficial effect is achieved by regulating the expression of FXR, G protein-coupled bile acid receptor (TGR5), CYP7A1 and ASBT proteins involved in bile acid metabolism [182]. Furthermore, the flavones can downregulate the expression of lipid genes genes FAS and SREBP-1c, while upregulating the levels of fatty acid oxidation genes AMPK and CPT1A. As a result, the TC, TG, LDL and VLDL contents in serum of ApoE-/- mice decreased, HDL-C level increased, and the progress of atherosclerosis attenuated [183].

Astragaloside IV, a small molecular bioactive saponin isolated from *Astragali radix* [184], was able to downregulate the expression of adipogenesis genes SREBP-1, ACC1, FAS and SCD1 via activating AMPK and ACC phosphorylation. Meanwhile, lipid accumulation, endoplasmic reticulum stress and hepatic steatosis induced by FFA in hepatocytes were alleviated [185]. In T2DM rat model, Astragaloside IV protect against diabetic cardiomyopathy by improving the lipid accumulation...
| No | MEPs                  | Intervention   | Animal model          | Dosage                  | Period   | Control  | Dosage | References |
|----|----------------------|----------------|-----------------------|-------------------------|----------|----------|--------|------------|
| 1  | Cinnamomi cortex     | Powder         | Albino Rats           | 2 and 4 g/kg            | 30 days  | /        | /      | [38]       |
|    |                      | Extract        | C57BL/6 J mice        | 1%                      | 14 weeks | /        | /      | [39]       |
|    |                      | Polyphenol     | Wistar rats           | 100 mg/kg               | 12 weeks | /        | /      | [40]       |
|    |                      | Extract        | White mice            | 2 mg, 4 mg and 8 mg/20 g| 28 days  | /        | /      | [41]       |
|    |                      | Extract        | Albino Rats           | 250 and 500 mg/kg       | 7 days   | Atorvastatin 10 mg/kg | [42] |
| 2  | Chrysanthemi flos    | Extract        | SD rats               | 0.2% and 0.4%           | 13 weeks | /        | /      | [50]       |
|    |                      | Extract        | SD rats               | 1, 2 and 4 g/kg         | 8 weeks  | Fenofibrate 0.02 g/kg | [51] |
|    |                      | Flavonoids, luteolin and luteoloside | SD rats | 100 mg/kg; 50 mg/kg; 25 mg/kg | 6 weeks  | Simvastatin 10 mg/kg | [53] |
| 3  | Citri sarcodactylis fructus | Polyphenols | mice                  | 50 mg/kg                | 11 weeks | /        | /      | [63]       |
|    |                      | Polyphenols    | Wistar rats           | 20 mg/Kg                | 90 days  | /        | /      | [64]       |
|    |                      | Polyphenols    | SD rats               | 10 mg/Kg                | 4 weeks  | /        | /      | [65]       |
|    |                      | Naringin       | C57BL/6 J Mice        | 25, 50 and 100 mg/kg    | 8 weeks  | /        | /      | [66]       |
| 4  | Crataegi fructus     | Extract        | SD rats               | 50 and 100 mg/kg        | 4 weeks  | /        | /      | [71]       |
|    |                      | Extract        | SD rats               | 5% and 10%              | 4 weeks  | /        | /      | [72]       |
|    |                      | Freeze-dried powder | ApoE−/− mice          | 1, 2, and 5 g/kg        | 12 weeks | /        | /      | [73]       |
|    |                      | Concentrated juice | KunMing mice        | 10, 15, and 20 ml/kg    | 5 weeks  | /        | /      | [76]       |
|    |                      | Pectin penta-oligogalacturonide | KunMing mice | 300 mg/kg              | 4 weeks  | /        | /      | [77]       |
|    |                      | Crude glycoprotein | KunMing mice          | 1.0, 1.5 and 2.0 g/kg   | 4 weeks  | /        | /      | [78]       |
|    |                      | Vitexin        | C57BL/6 J mice        | 5 mg/kg                 | 12 weeks | /        | /      | [79]       |
|    |                      | Preparation    | ApoE−/− mice          | /                      | 16 weeks | /        | /      | [80]       |
| 5  | Gardeniae fructus    | Extract        | SD rats               | 25, 50, and 100 mg/kg   | 6 weeks  | Metformin 100 mg/kg | [87] |
|    |                      | Geniposide     | Nrf2−/− C57BL/6 mice | 50, 75 and 100 mg/kg    | 19 h     | Fenofibrate 100 mg/kg | [88] |
|    |                      | Geniposide     | C57BL/6 and ApoE−/− mice | 50 mg/kg              | 13 weeks | /        | /      | [89]       |
|    |                      | Geniposide     | ApoE−/− mice          | 50 mg/kg                | 12 weeks | /        | /      | [90]       |
|    |                      | Geniposide     | ApoE−/− mice          | 50 and 100 mg/kg        | 4 weeks  | /        | /      | [91]       |
|    |                      | Genipin        | SD rats               | 12.5 and 25 mg/kg       | 12 days  | /        | /      | [93]       |
|    |                      | Genipin        | C57BL/6 J mice        | 5 and 20 mg/kg          | 9 weeks  | Rosiglitazone 2 mg/kg | [94] |
| 6  | Hippophae fructus    | Flavonoids     | KunMing mice          | 100, 200 and 400 mg/Kg  | 42 days  | /        | /      | [100]      |
|    |                      | Flavonoids     | C57BL/6 mice          | 100 and 300 mg/kg       | 9 weeks  | /        | /      | [101]      |
|    |                      | Sterol         | SD rats               | 100, 200 and 400 mg/Kg  | 42 days  | Simvastatin 3.5 mg/kg | [104] |
| 7  | Mori fructus         | Extract        | SD rats               | 4 g/kg                  | 4 weeks  | /        | /      | [110]      |
|    |                      | Dried fruit    | C57BL/6 J mice        | 100 and 300 mg/kg       | 3 months | /        | /      | [112]      |
|    |                      | Polysaccharides | db/db mice          | 200, 500 and 800 mg/kg  | 8 weeks  | /        | /      | [113]      |
|    |                      | Polysaccharides | Wistar rats           | 400 mg/kg               | 7 weeks  | /        | /      | [114]      |
### Table 2 (continued)

| No | MEPs | Intervention | Animal model | Dosage | Period | Control | Dosage | References |
|----|------|--------------|--------------|--------|--------|---------|--------|------------|
| 8  | Mori folium | Powder        | SD rats      | 0.9, 0.6, and 0.3 g/kg | 5 weeks | Atorvastatin | 6.0 mg/kg | [121] |
|    |      | Extract      | SD rats      | 0.5% and 1% | 4 weeks | /       | /      | [122, 123] |
|    |      | Extract      | Wistar rats  | 0.5%, 1% and 2% | 10 weeks | /       | /      | [116] |
|    |      | Flavonoids   | db/db mice   | 180 mg/kg | 7 weeks | Metformin | 200 mg/kg | [124] |
|    |      | Flavonoids   | SD rats      | 50, 100 and 200 mg/kg | / | Fenoalibra | 50 mg/kg | [125] |
|    |      | Polyphenols, fiber | SD rats | 0.8, 0.12, 0.48 and 0.6 g/kg | 6 weeks | Orlistat | 0.0324 g/kg | [126] |
|    |      | Extract      | CS7BL/6 mice | 0.5%, 1.0%, and 2.0% | 8 weeks | /       | /      | [127] |
|    |      | Polysaccharides | CS7BL/6 mice | 200, 400 and 800 mg/kg | 8 weeks | Orlistat | 25 mg/kg | [128] |
| 9  | Nelumbinis folium | Powder       | SD rats      | 600 mg/kg | 18 weeks | /       | /      | [131] |
|    |      | Nuciferine   | SD rats      | 20 mg/kg | 8 weeks | /       | /      | [133] |
|    |      | Nuciferine   | CS7BL/6 mice | 7.5, 15 and 30 mg/kg | 8 weeks | Metformin | 90 mg/kg | [134] |
|    |      | Nuciferine   | CS7BL/6 J mice | 0.3% | 8 weeks | /       | /      | [136] |
|    |      | Nuciferine   | SD rats      | 10 mg/kg | 8 weeks | Simvastatin | 10 mg/kg | [137] |
| 10 | Citri reticulatae pericarpium | Extract     | SD rats      | 5 g/kg | 4 weeks | Simvastatin | 4 mg/kg | [146] |
|    |      | Extract      | SD rats      | 1.25, 2.5 and 5 g/kg | 4 weeks | Simvastatin | 4 mg/kg | [148] |
|    |      | Extract      | SD rats      | 1.25, 2.5 and 5 g/kg | 6 weeks | Ezetimibe | 1 mg/kg | [149] |
|    |      | Extract      | CS7BL/6 mice | 5 and 10 g/kg | 12 weeks | Simvastatin | 2 mg/kg | [150] |
| 11 | Zanthoxyli pericarpium | Hydroxy-α-sanshool | Wistar rats | 9, 18 and 36 mg/kg | 4 weeks | Fenoalibra | 18 mg/kg | [157] |
| 12 | Dioscoreae rhizoma | Diosgenin   | Wistar rats  | 0.5% | 6 weeks | /       | /      | [162] |
|    |      | Resistant starch | golden hamsters | 0.5, and 1.5 g/100 g | 4 weeks | /       | /      | [164] |
| 13 | Polygonati rhizoma | Extract     | SD rats      | 1, 2 and 4 g/kg | 14 weeks | Resveratrol | 40 mg/kg | [165] |
|    |      | Extract      | SD rats      | 4 g/kg | 14 weeks | Simvastatin | 1.8 mg/kg | [170] |
|    |      | Polysaccharides | KunMing mice | 200, 400, and 800 mg/kg | 14 days | Simvastatin | 30 mg/kg | [171] |
|    |      | Polysaccharides | SD rats      | 120, 240, 480 mg/kg | 14 weeks | Simvastatin | 1.8 mg/kg | [172] |
|    |      | Saponin      | ICR mice    | 1, 1.5, and 2 g/kg | 4 weeks | Metformin | 0.5 g/kg | [173] |
|    |      | Syringaresinol-di-o-β-d-glucoside | SPF mice | 25, 50, and 75 mg/kg | 2 weeks | /       | /      | [174] |
| 14 | Astragali radix | Total flavones | CS7BL/6 J mice | 5, 25 and 50 mg/kg | 8 weeks | Metformin | 0.15 mg/kg | [182] |
|    |      | Total flavones | ApoE−/− mice | 10 and 20 mg/kg | 16 weeks | /       | /      | [183] |
|    |      | Astraaloside IV | SD rats | 80 mg/kg | 8 weeks | Metformin | 200 mg/kg | [186] |
| 15 | Puerariae radix | Extract     | CS7BL/6 mice | 100 and 300 mg/kg | 16 weeks | Metformin | 250 mg/kg | [193] |
|    |      | Puerarin     | SD rats      | 2 g/kg | 16 weeks | /       | /      | [194] |
|    |      | Puerarin     | SD rats      | 100 mg/kg | 8 weeks | /       | /      | [195] |
|    |      | Polysaccharides | db/db mice | 100 and 200 mg/kg | 6 weeks | Rosiglitazone | 10 mg/kg | [187] |
|    |      | PL-S2        | Wistar rats  | 50 mg/kg | 3 weeks | Simvastatin | 8 mg/kg | [196] |
in cardiomyocytes, decreasing the contents of TC, TG in serum and FFA in tissue, and elevating the plasma HDL-C level [186].

**Puerariae radix** (Gegen)

*Puerariae radix*, the dried root of the leguminous plant *Pueraria lobata* (Willd.) Ohwi or *Pueraria thomsonii* Benth, has been traditionally used as a source of medicine and food in China, Japan and Korea [187]. There are two different kinds of Chinese *Puerariae radix*, one is called Yege (*Puerariae lobatae radix*) and the other is Fenge (*Puerariae thomsonii radix*). Both of them contain isoflavones, the major bioactive constituents, including puerarin, daidzin, daidzein, genistin, genistein and other compounds [188]. Although used interchangeably in clinical practice, there are still distinctions between Yege and Fenge [189]. It is considered that Yege has better medicinal value attributes to its higher isoflavones, while Fenge is more suitable for eating due to being abundant in starch and sweet in taste [31, 190]. Currently, *Puerariae radix* is widely used to treat diseases such as hyperlipidemia, hypertension, coronary heart disease, liver injury, fever and diarrhea [191].

*Puerariae radix* plays a role in treating hyperlipidemia and other metabolic diseases through multiple potential mechanisms [192]. In obese mice model induced by a high-fat diet, *Puerariae radix* extract (100 or 300 mg/kg) administration for 16 weeks improved the levels of TC and HDL-C, glucose tolerance and liver lipid accumulation. The increased expression of peroxisome proliferator-activated receptor-γ coactivator (PGC)-1α proteins mediated by AMPK activation might be responsible for these effects [193].

Puerarin, the main component of *Puerariae radix*, improved dyslipidemia by decreasing the mRNA expression of lipogenic genes including SREBP-1c, FAS, SCD1 and HMGCR, while increasing the phosphorylation of AMPK and ACC, which lead to the reduction of TC content and lipid accumulation in HepG2 cells (Table 1 and 3) [194]. In rats model of type 2 diabetic induced by a high-fat diet combined with low-dose streptozotocin, puerarin treatment decreased serum TC, TG, LDL-C and

---

**Table 2** (continued)

| No | MEPs                        | Intervention          | Animal model | Dosage | Period | Control         | Dosage | References |
|----|-----------------------------|-----------------------|--------------|--------|--------|-----------------|--------|------------|
| 16 | Cassiae semen               | Extract SD rats       | 10 g/kg      | 4 weeks| Atorvastatin 10 mg/kg | [201] |
|    | Extract SD rats             | 54, 162 and 486 mg/kg | 4 weeks | Atorvastatin 10 mg/kg | [202] |
|    | Total aglycones (TA),      | CS7BL/6 mice          | TA 10 g/kg, RG 20 mg/kg, and AO 20 mg/kg | 3 weeks | / | / | [203] |
|    | rubrofusarin-6-β-gentiobioside (RG) and urantio-obtusin (AO) | Extract SD rats | 0.5, 2 g/kg | 6 weeks | Metformin 0.2 g/kg | [204] |
|    | Anthraquinone glycoside     | SD rats               | 10 and 20 mg/kg | 6 weeks | Polyene phosphatidylcholine | 23 mg/kg | [206] |
|    | 1,8-Dihydroxyanthraquinone | mice                  | 5 mg/kg      | 6 weeks | / | / | [207] |
| 17 | Caravaliae semen            | Total terpenoids and total flavonoids | Wistar rats 400 mg/kg | 3 weeks | Glibenclamide | 5 mg/kg | [213] |
|    | Protein extract SD rats     | 4 and 6 g/200 g       | 2 weeks | / | / | [215] |
| 18 | Lablab semen album          | Extract CS7BL/6 J mice | 25 mg/kg | 9 weeks | Milk thistle 100 mg/kg | [220] |
|    | Extract CS7BL/6 J mice      | 25, 50 and 100 mg/kg | 9 weeks | Milk thistle 100 mg/kg | [221] |
|    | 1,8-Dihydroxyanthraquinone | mice                  | 5 mg/kg      | 6 weeks | / | / | [207] |
| 19 | Persicae semen              | Amygdalin LDLR-/- mice | 1, 3 and 10 mg/kg | 4 weeks | / | / | [225] |
|    | Amygdalin ApoE-/- mice      | 0.04 and 0.08 mg/kg | 12 weeks | Simvastatin 2.57 mg/kg | [226] |
|    | Peach kernel oil ApoE-/- mice | 2 and 5 g/kg | 8 weeks | Simvastatin 5 mg/kg | [228] |
| 20 | Portulacae Herba            | Extract Wistar rats   | 400 mg/kg | 4 weeks | Atorvastatin 10 mg/kg | [235] |
|    | Extract Wistar rats         | 10 g/kg | 4 weeks | / | / | [236] |
|    | Extract albinorats          | 10% and 10% | 8 weeks | / | / | [237] |
|    | Extract Wistar rats         | 0.5% and 10% | 4 weeks | / | / | [238] |
|    | Extract CS7BL/6 mice        | 5% and 10% | 12 weeks | / | / | [239] |
It can downregulate the mRNA expression of SREBP-1c and SCD1, upregulate CPT1 and acyl-coenzyme A oxidase (ACOX), and restore the activity of hepatic lipase. As a result of glycolipid metabolism and oxidative stress improvement, hepatic steatosis was also ameliorated [195].

Polysaccharides isolated from *Puerariae radix* administered for 6 weeks were found to increase the content

| No | MEPs                              | Intervention | Cell model                                    | Concentration | Duration | References |
|----|-----------------------------------|--------------|----------------------------------------------|---------------|----------|------------|
| 1  | *Chrysanthemi flos*               | Extract      | HUVECs                                       | 50, 100, and 200 μg/mL | 24 h     | [51]       |
| 2  | *Citri sarcodactylis fructus*     | Extract      | 3T3-L1 cells                                 | 0.85 and 0.56 mg/ml | 5 days   | [60]       |
|    |                                  | Extract and main components             | HepG2 and Caco-2 Cells                        | 50 and 100 μg/mL | 24 h     | [61]       |
| 3  | *Crataegi fructus*                | Extract      | 3T3-L1 cells                                 | 50, 100, and 200 μg/mL | 24 h     | [72]       |
|    |                                  | Vitexin      | 3T3-L1 cells                                 | 10 and 50 μM   | 8 days   | [79]       |
| 4  | *Gardeniae fructus*               | Geniposide   | HepG2                                        | 0, 65, 130, 260, 390 and 520 μmol/L | 24 h     | [88]       |
|    |                                  | Geniposide   | HepG2 cells and Caco2 cells                  | 100 μM         | 12 and 24 h | [89]       |
|    |                                  | Geniposide   | RAW264.7 macrophage cells                    | 2.5, 5, 10, 20, 40 and 80 μM | 24 h     | [90]       |
|    |                                  | Geniposide   | RAW264.7 macrophage cells                    | 50, 100, and 200 μg/mL | 24 h     | [91]       |
|    |                                  | Genipin      | Primary hepatocytes                          | 20 μM          | 24 h     | [94]       |
| 5  | *Hippophae fructus*               | Flavonoids   | HL7702 cells                                 | 5, 10, 20, 40 and 80 μg/mL | 24 h     | (102)      |
|    |                                  | Kaempferol   | HepG2 Cells                                  | 5, 10 and 20 μM | 48 h     | (103)      |
|    |                                  | and kaempferide                  |                                              |               |          |            |
| 6  | *Mori fructus*                    | Extract      | 3T3-L1 cells                                 | 10, 50, 100, and 500 ng/mL | 7 days   | (111)      |
| 7  | *Mori folium*                     | Flavonoids   | L6 skeletal muscle cells                     | 5, 10, 20, 40 and 80 μg/mL | 24 h     | (124)      |
|    |                                  | Flavonoids   | HepG2 cells                                  | 1, 5, 10, 30, 60, 90, 150, and 180 μmol/L | 24 h     | (125)      |
|    |                                  | Extract      | HepG2 cells                                  | 2 μg/mL        | 24 h     | (127)      |
|    |                                  | Polysaccharides | HepG2 cells                  | 25, 50, 100, 150 and 200 μg/mL | 24 h     | (128)      |
| 8  | *Nelumbinis folium*               | Nucliferine  | Caco-2 and HT-29 cells                       | 0, 25, 50, 100 and 200 μM | 24 h     | (136)      |
|    |                                  | Nucliferine  | 3T3-L1 preadipocytes                        | 0, 2.5, 5, 10 and 20 μM | 24, 48, 72, 96 and 120 h | (138)      |
|    |                                  | Nucliferine  | THP-1 cells                                  | 5, 10 and 20 μmol/L | 24 h     | (139)      |
|    |                                  | Nucliferine  | THP-1 cells                                  | 2.5, 5, 10, and 20 μmol/L | 24 h     | (140)      |
| 9  | *Dioscoreae rhizoma*              | Diosgenin    | C2C12 cells                                  | 0, 20, 40 and 80 μM | 3 h      | (162)      |
| 10 | *Astragali radix*                 | Total flavones | HepG2 cells                  | 0, 2.5, 5, 10, 20 and 40 μg/mL | 24 h     | (182)      |
|    |                                  | Total flavones | HUVECs, RAW264.7, THP-1 cells and peritoneal macrophages | 6, 12 and 24 μg/mL | 12 h     | (183)      |
|    |                                  | Astragaloside iv | HepG2 cells                  | 50, 100, and 200 μg/mL | 24 h     | (185)      |
| 11 | *Puerariae radix*                 | Extract      | C2C12 cells                                  | 0.2 and 0.5 mg/mL | 24 h     | (193)      |
|    |                                  | Puerarin      | HepG2 cells                                  | 75 and 150 μM  | 24 h     | (194)      |
| 12 | *Canavaliae semen*                | Extract      | 3T3-L1 cells                                 | 100, 200, 400, and 1000 μg/mL | 48 h     | (212)      |
| 13 | *Persicae semen*                  | Amygdalin    | bone marrow-derived macrophages             | 25, 50, 100, 200, 400, and 800 μg/mL | 24 h     | (226)      |
|    |                                  | Peach kernel oil | HUVECs and RAW264.7 macrophage cells | 0.01, 0.05, 0.1, 0.15, and 0.2 μg/mL, 50, 100 and 200 μg/mL | 24 h     | (228)      |
of HDL-C in serum, but decrease the levels of TG, TC, LDL-C, and FFA. The underlying mechanism is through upregulating the mRNA expression of PPARα and LDLR while downregulating SREBP-1 and ACC [187]. Bile acids play a pivotal role in the lipid metabolism. The novel homogeneous polysaccharide PL-S2 derived from Puerariae radix exerts hypolipidemic function by facilitating bile acids synthesis and excretion mediated via the FXR signaling pathway [196].

Seeds

_Cassiae semen_ (Juemingzi)

_Cassiae semen_, also known as cassia seed, is the dried mature seed of _Cassia obtusifolia_ L. or _C. tora_ L. (Cassia minor) of Leguminosae [31, 32]. It grows in tropical Asian countries with strong vitality and is widely cultivated in Korea and China [197]. Cassia seed is popular as a functional roasted tea in China. TCM believes that it can nourish the liver, improve eyesight, relieve constipation and alleviate headache. It contains anthraquinones, naphthopyranones, fatty acids, polysaccharides, and other chemical ingredients [198]. Except for pharmacological activities of antihypertension, lowering blood sugar, relieving bowels, and antioxidation, it has shown potential therapeutic effects on dyslipidemia [199, 200], which is one of the promising MEPs for the development of lipid-lowering drugs and its derivates (Fig. 3).

Studies reported that cassia seed extract could effectively improve lipid profiles of hyperlipidemia rats, and reduce the contents of TC, TG and LDL-C in serum [201, 202]. The mechanism might be through regulating the gut microbiota [203]. In addition, the ethanol extract of cassia seed decreased the contents of TC and TG in blood and upregulated the mRNA expression of LDLR in a dose-dependent manner [204]. Cassia seed contains a variety of chemical components, among which anthraquinones are the most important pharmacologically active ingredients for lipid-lowering [198, 205]. Research indicated that the anthraquione glycoside isolated from cassia seed could regulate lipid metabolism by increasing PPARα expression and inhibiting SREBP-1c expression in the liver tissue of rats [206]. Moreover, the 1,8-dihydroxy-anthraquinone separated from cassia seed can upregulate and downregulate the protein expression of CYP7A1 and HMGCR, respectively, thereby modulating cholesterol metabolism and reducing the contents of TG, TC, and LDL-C in serum of hyperlipidemia mice [207].

_Canavaliae semen_ (Daodou)

_Canavaliae semen_, also called sword bean or Jack bean, is the mature dried seeds of the _Canavalia gladiata_ (Jacq.) DC of family Legume [31, 32]. In Asia, young pods and seeds of sword bean are consumed as green vegetables with desirable nutrients of protein, fatty acids, amino acids, minerals and starch. In Latin America, roasted seeds are usually used to prepare a coffee-like beverage [208]. Sword bean contains phenols, flavonoids, urease, concanavalin, gallic acid, and erythrocyte lectin. These bioactive compounds endow it with antioxidant, antibacterial, antiangiogenic, immunomodulatory and anticancer activities [209, 210]. In addition, it has potential treatment effects on metabolic diseases such as dyslipidemia, obesity and diabetes.

In states of overnutrition, excess calories are stored in the form of triglycerides and accumulated in white adipose tissue, leading to dyslipidemia and obesity [211].
The bacillus subtilis-fermented white sword bean extract can phosphorylate AMPK in the early stage of adipocyte differentiation, inhibit the mRNA expression of aP2 and adiponectin, as well as reduce the protein levels of C/EBPα, PPARγ, and FAS, which results in the decrease of TG accumulation. Concurrently, it can increase the mRNA expression of PPARα, ACOX, and long-chain acyl coenzyme A dehydrogenase (LCAD) as well as the protein levels of pHSL and ATGL, to promote lipolysis in mature 3T3-L1 adipocytes [212]. Total triterpenoids and total flavonoids in sword bean have been revealed to improve serum lipid profiles, body weight, blood glucose and antioxidant indexes [213, 214]. Moreover, in hypercholesterolemic rats, sword bean protein extract (2 or 3 g/100 g) intervention for 2 weeks was found to lower the levels of TC, TG, LDL-C and VLDL-C in blood whereas increasing the content of HDL-C [215].

**Lablab semen album (Baibiandou)**

*Lablab semen album*, commonly known as white hyacinth bean, is the dried mature seed of *Dolichos lablab* L. belongs to family Fabaceae [31, 32]. For centuries, it has been traditionally used in Asian medicine such as China and South Korea to treat gastrointestinal disorders. In India, cooked hyacinth bean pods are eaten to alleviate diarrhea, nausea, vomiting and poor appetite [216, 217]. White hyacinth bean contains chemical components including flavonoids, saponins, coumarins, terpenes, alkaloids, tannins, alcohols, phenols, steroids and essential oils [218]. Pharmacological studies have shown that it has hypolipidemic, hypoglycemic, anti-inflammatory, antioxidant, and hepatoprotective properties [219].

In obese mice with dyslipidemia, the dietary administration of hyacinth bean (25 mg/kg/day) for 9 weeks significantly decreased the levels of TC, TG, LDL-C and FFA in serum as well as alleviated hepatic steatosis compared to model group. Metabolomics results indicated that the attenuation of amino acid, lipid, glucose, bile acid metabolism and glycerolipid/free fatty acid (GL/FFA) cycle is the potential mechanism for improving dyslipidemia and obesity [220]. Furthermore, white hyacinth bean could ameliorate lipid profiles and NAFLD via down-regulating the expression of mRNA and protein that mediated fatty acid uptake and lipid droplet accumulation [221]. Nonetheless, which chemical components play a role in lipid-lowering still needs further study.

**Persicae semen (Taoren)**

*Persicae semen*, also called peach kernel, is the dried and mature seed of *Prunus persica* (L.) Batsch of Rosaceae or *P. davidiana* (Carr.) Franch. of Yamada [31, 32]. Peach kernel is conventionally used to activate blood circulation, remove stasis, loosen the bowel, and relieve constipation [222]. Modern pharmacological studies have found that peach kernel contains a variety of chemical components, including volatile oils, cyanogenic glycosides, flavonoids, sterols, aromatic glycosides, fatty acids, phenylpropanoids, nucleosides and trace elements [223]. Biological activities such as cardio-cerebral vascular system protection, anti-inflammation, anti-tumor, immunomodulation, liver and kidney protection have been found in peach kernel [224].

Amygdalin, the main cyanogenic glycoside compound of peach kernel, has the functions of improving dyslipidemia and atherosclerosis. In LDLR/-/- mice fed with a high-fat and high-cholesterol diet, amygdalin supplementation decreased the levels of TC, TG and LDL-C in serum whereas increased HDL-C. In addition, the inflammatory reaction and the development of atherosclerosis were attenuated [225]. In high-fat diet ApoE/-/- mice, the blood lipid profiles, body weight, inflammatory cytokines, and atherosclerotic plaque area were all decreased after injection of amygdalin at the concentration of 0.08 or 0.04 mg/kg for 12 weeks [226]. Similar effects have also been found in peach kernel oil, which contains unique fatty acids including oleic acid (ω-9) and linoleic acid (ω-6) that are beneficial to the human body [227]. The administration of peach kernel oil reduced TC, TG and LDL-C levels whereas elevated HDL-C levels in mice serum. Moreover, the formation of atherosclerotic plaque was inhibited by down-regulating the expression of inflammatory genes and proteins [228].

**Whole herbs**

*Portulaca herba* (Machixian)

*Portulaca herba*, also known as purslane, is the herbaceous weed of *Portulaca oleracea* L. belonging to the family Portulacaceae [31, 32]. It is an annual herb widespread in many countries and areas such as China, India, France, and Spain, usually eaten as a potherb with succulent leaves [229]. As a traditional medicinal herb, purslane possesses pharmacological properties including anti-inflammation, antibacterial, antioxidation, hypolipidemia, hypoglycemia, and hepatoprotection [229, 230]. It can be used to treat dermatosis, gynecological diseases and intestinal bacterial infections [231]. There are abundant bioactive ingredients in purslane such as flavonoids, polysaccharides, phenolic acids, alkaloids, triterpenoids, and essential fatty acids [232]. Besides, purslane riches in essential ω-3 and ω-6 fatty acids, ascorbic acid, α-tocopherol and β-carotene [233], which have beneficial effects on cardiovascular disease, diabetes, cancer, dementia, depression, visual and neurological development [234].

Studies reported that purslane extract has an excellent hepatoprotective property and lipid-lowering effects. It
Omega-3 fatty acids are likely to be the effective ingredients in the treatment of metabolic syndrome and prevention of cardiovascular diseases. Based on this, the role of MEPs in the treatment of metabolic syndrome and cardiovascular disease deserves further exploration.

MEPs are optimal candidates and deserve further study. Flavonoids, phenolic compounds and omega-3 fatty acids are likely to be the effective ingredients in the treatment of metabolic syndrome and prevention of cardiovascular diseases. Based on this, the role of MEPs in the treatment of metabolic syndrome and cardiovascular disease deserves further exploration.

Conclusion and perspective

In general, MEPs, including the extract and bioactive compounds, can regulate the concentrations of serum TG, TC, LDL-C and HDL-C to modify dyslipidemia. As shown in Table 1, the main effective components of MEPs for dyslipidemia treatment include flavonoids (kaempferol, naringin, quercetin, luteolin), isoflavones (puerarin), saponins (astragaloside IV, diosgenin), iridoid glycosides (geniposide, genipin), alkaloids (nuciferine), polysaccharides (pectin), sterols, polyphenols, anthraquinones and other bioactive components. The lipid regulation mechanism involves the whole process of lipid absorption, synthesis, transport, decomposition and excretion: (1) MEPs decrease intestinal epithelial cell permeability and inhibit lipid absorption. (2) MEPs inhibit de novo cholesterol biosynthesis, fatty acid uptake and triglyceride synthesis. (3) MEPs promote lipid catabolism by increasing cholesterol efflux and accelerating fatty acid oxidation. (4) MEPs regulate enterohemepatic circulation of bile acids to decrease cholesterol. They can promote the conversion of cholesterol into bile acids and inhibit the bile acids reabsorption. (5) MEPs promote lipid transport and distribution by regulating apolipoprotein, HDL-C formation and reverse cholesterol transport. (6) MEPs modulate intestinal flora and relieve insulin resistance to improve lipid metabolism disorder (Fig. 1, Fig. 2 and Table 1). Notably, they can not only regulate lipid metabolism, but also possess potential benefits of lowering blood sugar, anti-obesity, resist atherosclerosis, antioxidation, and anti-inflammation, which contribute to the prevention of cardiovascular diseases. Based on this, the role of MEPs in the treatment of metabolic syndrome and cardiovascular disease deserves further exploration.
choler: H: Liver lipase; HMGR: Hydroxymethyl glutaryl-CoA reductase; LCAD: Long-chain acyl coenzyme A dehydrogenase; LCAT: Lecithin cholesterol acyltransferase; LDL-C: Low-density lipoprotein cholesterol; LDLR: Low-density lipoprotein receptor; LPL: Lipoprotein lipase; LXRα: Liver X receptor α; NPC1L1: Niemann-Pick C1 Like 1; pChem: Pancreatic cholesterol ester hydrolase; PPARα: Peroxisome proliferator-activated receptors α; SCD1: Stearyl-CoA desaturase 1; SREBP: Sterol regulatory element-binding protein; TC: Total cholesterol; TG: Triglyceride; TGR5: G protein-coupled bile acid receptor; UCP2: Uncoupling protein 2.

Acknowledgements
Not applicable.

Author contributions
YH and MH performed the literature search and YH wrote the original draft. X.C, SY and DJZ contributed to the manuscript draft and revisions. PL and LF reviewed the article. All authors read and approved the final manuscript.

Funding
We are grateful for the financial support from the Scientific and Technological Innovation Project of China Academy of Chinese Medical Sciences (No. CI 2021A103001 and No. CI 2021A103008), the National Key Research and Development Program of China (Grant No. 2019YFC1708404), and the National Natural Science Foundation of China (No. 81774128).

Availability of data and materials
Not applicable.

Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 China Academy of Chinese Medical Sciences Guang'anmen Hospital, Beijing 100053, China. 2 China Academy of Chinese Medical Sciences, Beijing 100700, China. 3 Beijing University of Chinese Medicine, Beijing 100029, China. 4 The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China. 5 Henan Key Laboratory of Children's Genetics and Metabolic Diseases, Children's Hospital Affiliated to Zhengzhou University, Henan Children's Hospital, Zhengzhou 450018, China. 6 Beijing University of Chinese Medicine Third Affiliated Hospital, Beijing 100029, China.

Received: 4 May 2022 Accepted: 29 August 2022
Published online: 29 September 2022

References
1. Ference BA, Kastelein JJP, Catapano AL. Lipids and lipoproteins in 2020. JAMA. 2020;324(6):595–6.
2. Shengshou H. China TWCotRoCHaDi. Report on cardiovascular health and diseases burden in China: an updated summary of 2020. Chin Circ J. 2021;36(6):521–45.
3. Defesche JC, Gidding SS, Harada-Shiba M, Hegele RA, Santos RD, Wierzbicki AS. Familial hypercholesterolaemia. Nat Rev Dis Primers. 2017;3:17093.
4. Murray CJ, Lopez AD. Measuring the global burden of disease. N Engl J Med. 2013;369(5):446–57.
5. Visseren FLJ, Mach F, Smulders YM, Carvalho D, Koskinas KC, Back M, et al. 2011 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2011;42(34):3227–337.
6. NCDRF Collaboration. Repositioning of the global epicentre of non-optimal cholesterol. Nature. 2020;582(7810):73–7.
7. Mortensen MB, Nordestgaard BG, Afzal S, Falk E. ACC/AHA guidelines superior to ESC/EAS guidelines for primary prevention with statins in non-diabetic Europeans: the Copenhagen general population study. Eur Heart J. 2017;38(8):S86–94.
8. Rossello X. Lifetime risk estimation in atherosclerotic cardiovascular disease: where inflammation meets lipoprotein(a). J Am Coll Cardiol. 2021;78(11):1095–6.
9. Ibanez B, Fernandez-Ortiz A, Fernandez-Friera L, Garcia-Lunar I, Andres V, Fuster V. Progression of early subclinical atherosclerosis (PESA) study: JACC focus seminar 7/8. J Am Coll Cardiol. 2021;78(2):156–79.
10. Collins R, Reith C, Emberson J, Armitage J, Baitent C, Blackwell L, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388(10059):2532–61.
11. Pergolini JJ, Coruzzi KL, Colelli RD, Olsson H, LeQuang JA, Al-Saadi J, et al. Statins and muscle pain. Expert Rev Clin Pharmacol. 2020;13(3):299–310.
12. Lv S, Yu H, Liu X, Gao X. The study on the mechanism of hugan tablets in treating drug-induced liver injury induced by atorvastatin. Front Pharmacol. 2021;12:683707.
13. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–88.
14. Soppe J, Lehrke M, Marx N, Jankowski J. Nolos H. Lipoproteins and lipids in cardiovascular disease: from mechanistic insights to therapeutic targeting. Adv Drug Deliv Rev. 2020;159:4–33.
15. Huang K, Zhang P, Zhang Z, You J, Wang C, Zhang H, et al. Traditional Chinese medicine (TCM) in the treatment of COVID-19 and other viral infections: efficacies and mechanisms. Pharmacol Ther. 2021;225:107843.
16. Wang S, Fu JL, Hao HF, Jiao YN, Li PP, Han SY. Metabolic reprogramming by traditional Chinese medicine and its role in effective cancer therapy. Pharmacol Res. 2021;170:105728.
17. Liu C, Huang Y. Chinese herbal medicine on cardiovascular diseases and the mechanisms of action. Front Pharmacol. 2016;7:469.
18. Xie G, Tang X, Liang X, Liu H, Zhang S. The orignation, connotation, and definition of one root of medicine and food. Mod Chin Med. 2020;22(9):1423.
19. Yang M, Sheng P. Medicinal and edible resources in Xinjiang: current status and prospects. Chin J Exp Tradit Med Formul. 2021;27(13):234–43.
20. Pollastro F, Minnasi A. Exploring the universe of natural products: recent advances in synthesis, isolation and structural elucidation. Plants (Basel). 2021;10(11):2368.
21. Yuan H, Ma Q, Ye L, Piao G. The traditional medicine and modern medicine from natural products. Molecules. 2016;21(5):559.
22. Atanasescu AG, Zoteiev SB, Dirsch VM, Supuran CT. Natural products in drug discovery: advances and opportunities. Nat Rev Drug Discov. 2021;20(3):200–16.
23. Yang G, Su F, Chen M. Origin and prospect of homology medicine and food. Mod Chin Med. 2021;23(11):1851–6.
24. Mollazadeh H, Mahdian D, Hosseinzadeh H. Medicinal plants in treatment of hypertriglyceridemia: A review based on their mechanisms and effectiveness. Phytomedicine. 2019;53:43–52.
25. El-Tantawy WH, Temraz A. Natural products for controlling hyperlipidemia: review. Adv Physiol Biochem. 2019;12(2):128–35.
26. Yuan H, Kishi H, Kobayashi S. Add-on therapy with traditional Chinese medicine: An efficacious approach for lipid metabolism disorders. Pharmacol Res. 2018;134:200–11.
27. Hunter FM, Hegele RA. Functional foods and dietary supplements for the management of dyslipidemia. Nat Rev Endocrinol. 2017;13(5):278–88.
28. Xie W, Zhao Y, Du L. Emerging approaches of traditional Chinese medicine formulas for the treatment of hyperlipidemia. J Ethnopharmacol. 2012;140(2):345–67.
29. National Health Commission of P. R. China. Management approach of hyperlipidemia in the treatment of hypertriglyceridemia. Chin J Tradit Chin Med. 2017;3:17093.
30. Hunter FM, Hegele RA. Functional foods and dietary supplements for the management of dyslipidemia. Nat Rev Endocrinol. 2017;13(5):278–88.
31. Xie W, Zhao Y, Du L. Emerging approaches of traditional Chinese medicine formulas for the treatment of hyperlipidemia. J Ethnopharmacol. 2012;140(2):345–67.
32. Hunter FM, Hegele RA. Functional foods and dietary supplements for the management of dyslipidemia. Nat Rev Endocrinol. 2017;13(5):278–88.
33. Xie W, Zhao Y, Du L. Emerging approaches of traditional Chinese medicine formulas for the treatment of hyperlipidemia. J Ethnopharmacol. 2012;140(2):345–67.
30. National Health Commission of P.R. China. List of 9 pilot food and Chi-
inese medicine homologous substances according to tradition. 2020.
http://www.nhc.gov.cn/spxs/202001/t20200112ec2ca0414645d9b14
acc249db854df.html. Accessed on 26 Apr 2022.
31. Huang L, Chen M. Interpretation of medicine and food homologous
substances. 1st ed. Beijing: People's Medical Publishing House; 2021. p.
28–468.
32. Pharmacopoeia Committee of P. R. China. Pharmacopoeia of People's
Republic of China. Beijing: China Medical Science and Technology Press;
2020. p. 12–315.
33. Shalaby MA, Saifan HY. Some pharmacological effects of cinnamon
and ginger herbs in obese diabetic rats. J Intercult Ethnopharmacol.
2014;3(4):144–9.
34. Ranasinghe P, Perera S, Gunatilake M, Abeywardene E, Gunapala N,
Premakumara S, et al. Effects of Cinnamonum zeylanicum (Ceylon cin-
namon) on blood glucose and lipids in a diabetic and healthy rats
model. Pharmacognosy Res. 2012;4(2):73–9.
35. Liu Y, An T, Wan D, Yu B, Fan Y, Pei X. Targets and mechanism used by
Cinnamaldehyde, the main active ingredient in Cinnamon, in the treat-
mament of breast cancer. Front Pharmacol. 2020;11(1751):582719.
36. Mbaveng AT. Medicinal spices and vegetables from Africa: therapeu-
tic potential against metabolic, infectious, inflammatory and systemic
diseases. London, UK: Academic Press; 2017. p. 385–95.
37. Naeef AF, Mohammed AH, Mubarak AN. Effects of cinnamon
(Cinnamo-
mum cassia) consumption on serum lipid profiles in Albino rats. J Lipids.
2020;9:168.
38. Zeynep T, Cemal O, Nurhan S, Vijaya J, Kazim S. Cinnamon polyphenol
polyphenol fraction on lipid transfer protein of Chrysanthemum morifo-
lum cv. Hang-ju induced by oxidative stress. Pharm Biol.
2021;59(1):40–6.
39. Yang PF, Yang YN, He CY, Chen ZF, Yuan QS, Zhao SC, et al. New
caffeoylquinic acid derivatives and flavanone glycoside from the flow-
ers of Chrysanthemum morifolium and their bioactivities. Molecules.
2019;24(5):850.
40. Sun J, Wang Z, Chen L, Sun G. Hydrolipidic effects and preliminary
mechanism of Chrysanthemum flavonoids, its main components
luteolin and luteolose in hyperlipidemia rats. Antioxidants (Basel).
2021;10(8):1309.
41. Mannucci C, Navarra M, Calapai F, Squeri R, Gangemi S, Calapai G. Cli-
nical pharmacology of citrus bergamia: a systematic review. Phytother.
Res. 2017;31(1):27–39.
42. Nauman MC, Johnson JJ. Clinical application of bergamot (Citrus berga-
mina) for reducing high cholesterol and cardiovascular disease markers.
Integr Food Nutr Metab. 2019;6(2):1–7.
43. Luo SM, Wu MH, Zhou Y, Huang ZH, Zhang Y, Ma ZG, et al. Herbal study
on original plant and medicinal and edible values of Citri Sarco-
dactylis Fructus. Chin J Chin Mater Med. 2020;45(16):3997–4003.
44. Zhao Y, Hu H, Peng T, Deng F, Xiang B, Huang Y. Research progress
on chemical components, pharmacological action, develop-
ment and application of Bergamot. Lishizhen Med Mater Med Res.
2018;29(1):2734–6.
45. Gabriele M, Frassinetti S, Saltavuturo L, Montero L, Dinelli G, Longo
V, et al. Citrus bergamia powder: Antioxidant, antiinflammatory and anti-
inflammatory properties. J Funct Foods. 2017;31:255–65.
46. Mollace V, Sacco I, Janda E, Malara C, Ventrice D, Colica C, et al. Hy-
dropoetic and hypoglycaemic activity of bergamot polyphenols:
from animal models to human studies. Fitoterapia. 2011;82(3):309–16.
47. Ballistreri G, Amenta M, Fabroni S, Consoli V, Grosso S, Vanella L, et al.
Evaluation of lipid and cholesterol-lowering effect of bioflavonoids
from bergamot extract. Nat Prod Res. 2021;35(23):3378–83.
48. Huang Y, Tocmo R, Nauman MC, Hauagha MA, Johnson JJ. Defining the
cholesterol lowering mechanism of Bergamot (Citrus bergamia) extracts
in HepG2 and Caco-2 Cells. Nutrients. 2021;13(9):3156.
49. Salerno R, Casale F, Calandruccio C, Procaccio A. Characterization of
flavonoids in Citrus bergamia (Bergamot) polyphenolic fraction by
liquid chromatography–high resolution mass spectrometry (LC/HRMS).
PharmaNutrition. 2016;4:1-7.
50. Wu M, Liu L, Xing Y, Yang S, Li H, Cao Y. Roles and mechanisms of Haw-
thorn and its extracts on atherosclerosis: A review. Front Pharmacol.
2020;11:118.
51. Dong QJ, Chen JP, Gong SX, Xu J, Xu X, Zhang TJ. Research progress
on chemical constituents and pharmacological effects of Caragae
Fructus and predictive analysis on Q-Marker. Chin Tradit Herbal Drugs.
2021;52(09):2801–18.
69. He Z, Kwek E, Hao W, Zhu H, Liu J, Ma K, et al. Hawthorn fruit extract reduced trimethylamine-N-oxide (TMAO)-exacerbated atherogenesis in mice via anti-inflammation and anti-oxidation. Nutr Metab (Lond). 2021;18(116).

70. Orhan IE. Phytochemical and pharmacological activity profile of *Cra* taequa *oxyacantha* L. (Hawthorn) - a cardiotoxic herb. Curr Med Chem. 2018;25(7):4854–65.

71. Hu C, Zhang Y, Liu G, Liu Y, Wang J, Sun B. Un targeted metabolite profiling of adipose tissue in hyperlipidemia rats exposed to Hawthorn ethanol extracts. J Food Sci. 2019;84(4):717–25.

72. Lee JJ, Lee HJ, Oh SW. Antiobesity effects of Sansa (*Crataegus fructus*) on 3T3-L1 cells and on high-fat-high-cholesterol diet-induced obese rats. J Med Food. 2017;20(1):19–29.

73. Qi J, Wang QZ, Yang J, Cai BM, Yu D. Effects of *Crateaque* cuneata Sieb. et Zucc. and *Crataegus* pinnatifida Bge Cratae in high-fat diet-fed apolipoprotein e-knockout mice via regulating gut microbiota. Chin Med. 2019;864:172728.

74. Orhan IE. Phytochemical and pharmacological activity profile of *Crateaque* oxyacantha L. (Hawthorn) - a cardiotonic herb. Curr Med Chem. 2022;25(10):54–9.

75. Zheng LX, Jiang ZY, Wang JN, Li XF, Xu LS. Optimization of extraction technology of Hawthorn polysaccharides and its hypoglycemic and hypolipidemic activity. Sci Technol Food Ind. 2019;40(13):119.

76. Ning SY, Teng D, Mu YN, Wang X, Sun YX. Study on the mechanism of Hawthorn powder regulating blood lipid of high-fat diet mice based on intestinal microecology. Chin Tradit Pat Med. 2020;42(11):3062–9.

77. Zhu R, Hou Y, Sun Y, Li T, Fan J, Chen G, et al. Pectin penta-oligogalacturonide suppresses intestinal bile acids absorption and down-regulates the FXR-FGF15 axis in high-cholesterol fed mice. Food Sci Technol. 2017;42(04):67–72.

78. Zhu R, Hou Y, Sun Y, Li T, Fan J, Chen G, et al. Pectin penta-oligogalacturonide suppresses intestinal bile acids absorption and down-regulates the FXR-FGF15 axis in high-cholesterol fed mice. Food Sci Technol. 2017;42(04):67–72.

79. Gao XJ, Luo SY, Tang KJ, Luo QS. Effect of crude hawthorn glycoprotein on hypolipidemic and antioxidant activity in high-fat mice. Food Fruits Ind. 2021;47(01):138–42.

80. Peng Y, Sun Q, Wu H, He Y, Jin W, Yuan L, et al. Vitexin ameliorates high fat diet-induced obesity in male C57BL/6j mice via the AMPKalpha-mediated pathway. Food Funct. 2019;10(4):1940–7.

81. Yang Y, Yao X, Li H, Shanha (*Frcatus Cratoe*) attenuates atherosclerosis in high-fat diet-fed apolipoprotein e-knockout mice via regulating gut flora. China Arch Tradit Chin Med. 2021;39(12):51–4.

82. Chen L, Li M, Yang Z, Tao W, Wang P, Tian X, et al. *Gardenia* jasminoides Ellis: ethnopharmacology, phytochemistry, and pharmacological and industrial applications of an important traditional Chinese medicine. J Ethnopharmacol. 2020;257:112699.

83. Toppo E, Darwin SS, Esakimastu S, Stalin A, Balakrishna K, Sivasankaran K, et al. Anthi hyperlipidemic and hepatoprotective effects of Gardenia A in cellular and high fat diet fed rodents models. Chem Biol Interact. 2017;269/9–17.

84. Xiao W, Li S, Wang S, Ho CT. Chemistry and bioactivity of *Gardenia* jasminoides. J Food Drug Anal. 2017;25(2):43–61.

85. Lv S, Ding Y, Zhao H, Liu S, Zhang J, Wang J. Therapeutic potential and effective components of the Chinese Herb Gardeniae Fructus in the treatment of senile disease. Aging Dis. 2018;9(6):1153–64.

86. Zhou YX, Zhang RQ, Rahman K, Cao ZX, Zhang H, Peng C. Diverse pharmacological activities and potential medicinal benefits of Genipose. Evid Based Complement Alternat Med. 2019;2019:4925682.

87. Tie F, Ding J, Hu N, Dong Q, Chen Z, Wang H. Kaempferol and kaemp feride attenuate oleic acid-induced lipid accumulation and oxidative stress in HepG2 cells. Int J Mol Sci. 2021;22(16):8847.

88. Yuan Q, Zhao L. The mulberry (*Morus alba*) consumption on health outcomes: a mini-review. Antioxidants (Basel). 2018;7(5):69.

89. Yuan Q, Zhao L. The mulberry (*Morus alba*) fruit-a review of characteristic components and health benefits. J Agric Food Chem. 2017;65(48):10383–94.

90. Guo S, Bai L, Ho CT, Bai N. Characteristic components, biological activities and future prospective of *Fructus Mori*: a review. Curr Pharm Rep. 2018;4(3):210–9.

91. Lee S, Lee MS, Chang E, Lee Y, Lee J, Kim J, et al. Mulberry Fruit Extract Promotes Serum HDL-cholesterol levels and suppresses hepatic microRNA-33 expression in rats fed high cholesterol/choleic acid diet. J Nutrients. 2020;12(9):1499.
112. Suriya C, Usana C, Rachanee C, Watcharokorn D, Kittiwoot T-o, Supaporn H et al. Chinese Medicine (2022) 17:113
113. Zhang R, Zhang Q, Zhu S, Liu B, Liu F, Xu Y. Mulberry leaf (Morus alba) ameliorates obesity-induced hepatic lipogenesis, fibrosis, and oxidative stress in high-fat diet-fed mice. Genes Nutr. 2015;10(6):46.
114. He L, Zhou W, Wang C, Yang F, Chen X, Zhang Q. Effect of cellulase and modulating intestinal microflora. Sci Rep. 2017;7:12041.
115. Huang J, Wang Y, Ying C, Liu L, Lou Z. Effects of mulberry leaf on experimental hyperlipidemia rats induced by high-fat diet. J Dairy Sci. 2018;16(2):547–56.
116. Lee E, Lee MS, Chang E, Kim CT, Choi AJ, Kim IH, et al. High hydrostatic pressure extract of mulberry leaves ameliorates cardiovascular and liver histopathological changes in high-fat diet-induced hyperlipidemic mice. J Tradit Complement Med. 2020;22(01):135–8.
117. Li A, Wang N, Li N, Li B, Yan F, Song Y, et al. Modulation effect of chenpi ingredient derived from lotus leaf, lights up the way for the potential ingredient to ameliorate cardiovascular and liver histopathological changes in high-fat diet-induced hyperlipidemic mice. J Tradit Complement Med. 2021;11:46.
118. Ye LH, Kong LT, Yan MZ, Cao FR, Wang LS, Liao YH, et al. Lotus leaf alkaloid fraction can strongly inhibit CYP2D6 isoenzyme activity. J Ethnopharmacol. 2016;194:913–7.
119. Li M, Zhao Z, Xuan J, Li Z, Ma T. Advances in studies on chemical constituents and pharmacological effects of lotus leaves. J Laojiu Univ Tradit Chin Med. 2020;22(01):135–8.
120. Lou ZH, Cheng B, Xia BH, Wang YP, Xu H, Zhang GJ. Effects of Foliol Nelumbinis on experimental nonalcoholic fatty liver disease induced by high glucose and high fat diet. Chin J Chin Mater Med. 2017;32(05):2169–73.
121. Wang X, Yao L, Jia Y, Chen L, Yang Y, Wu Li, et al. Nuciferine, an active ingredient derived from lotus leaf, lights up the way for the potential treatment of obesity and obesity-related diseases. Pharmacol Res. 2022;175: 106002.
neurons by inhibiting two-pore potassium channels. Nat Neurosci. 2008;11(7):772–9.

154. Wagner H, Bauer R, Melchert D, Xiao PG, Staedlinger A. Pericarpium Zanthoxyli Huo-piao. In: Chromatographic fingerprint analysis of herbal medicines volume I. Berlin, Germany: Springer-Verlag; 2011. p. 191–202.

155. Zhang M, Wang J, Zhu L, Li T, Jiang W, Zhou J, et al. Zanthoxyllum Bunanoeum maxim (Rutaceae): a systematic review of its traditional uses, botany, phytochemistry, pharmacology, pharmacokinetics, and toxicity. Int J Mol Sci. 2017;18(10):2172.

156. Omboito JO. Phytochemistry and pharmacology of the genus Zanthoxyllum (Rutaceae): a review. Nat Prod J. 2021;11(11):121–43.

157. Wang L, Fan W, Zhang M, Zhang Q, Li L, Wang J, et al. Antiobesity, regulation of lipid metabolism, and attenuation of liver oxidative stress effects of hydroxy-alpha-sanshoil isolated from Zanthoxylum bungeanum on high-fat diet-induced hyperlipidemic rats. Oxid Med Cell Longev. 2019;2019:5852494.

158. Obiedegwu JE, Lyons JB, Chikala CA. The Dioscorea genus (yam)—an appraisal of nutritional and therapeutic potentials. Foods. 2020;9(9):1304.

159. Okwu D, Ndu C. Evaluation of the phytoneutrients, mineral and vitamin contents of some varieties of yam (Dioscorea sp.). Int J Mol Med Adv Sci. 2020;6(2):199–203.

160. Zhang L, Ng TB, Lam JK, Wang SW, Lao L, Zhang KY, et al. Research and development of proteins and peptides with therapeutic potential from yam tubers. Curr Protein Pept Sci. 2019;20(3):277–84.

161. Jesus M, Martins AP, Gallardo E, Silvestre S. Diosgenin: Recent highlights. Int J Biol Macromol. 2020;150:446–55.

162. Li T, Teng H, An F, Huang Q, Chen L, Song H. The beneficial effects of Diosgenin supplementation prevents lipid accumulation and induces skeletal muscle fiber hypertrophy in rats. J Nutr Sci Vitaminol (Tokyo). 2019;65(S):421–9.

163. Meenu M, Xu B. A critical review on anti-diabetic and anti-obesity effects of dietary resistant starch. Crit Rev Food Sci Nutr. 2019;59(18):3019–31.

164. Li T, Teng H, An F, Huang Q, Chen L, Song H. The beneficial effects of purple yam (Dioscorea alata L.) resistant starch on hyperlipidemia in high-fat-fed hamsters. Food Funct. 2019;10(5):2642–50.

165. Yang XX, Wang X, Shi TT, Dong JC, Li FJ, Zeng LX, et al. Mitochondrial dysfunction in high-fat diet-induced nonalcoholic fatty liver disease: the alleviating effect and its mechanism of Polygonatum kingianum. Biomed Pharmacother. 2019;111:109083.

166. Su HF, Shaker S, Kuang Y, Zhang M, Ye M, Qiao X. Phytochemistry and cardiovascular protective effects of Huang-Qi (Polygonatum sibiricum). Med Res Rev. 2021;41(4):1999–2036.

167. Wang Z, Li XL, Hong KF, Zhao TT, Dong RX, Wang WM, et al. Total flavonoids of Astragalus ameliorated bile acid metabolism dysfunction in diabetes mellitus model. Evid Based Complement Alternat Med. 2021;2021:6675567.

168. Ma C, Zhang J, Yang S, Hua Y, Su J, Shang Y, et al. Astragalus flavone ameliorates atherosclerosis and hepatic steatosis via inhibiting lipid-disorder and inflammation in Apo(E−/−) mice. Front Pharmacol. 2020;11:610550.

169. Qian W, Qian Q, Cai X, Han R, Wang Y, Zhang X, et al. Astragaloside IV inhibits oxidized lowdensity lipoprotein-induced endothelial damage via upregulation of miR140p. Int J Mol Med. 2019;43(3):847–56.

170. Zhou B, Zhou DL, Wei WX, Zhong RX, Yu J, Sun L. Astragaloside IV attenuates free fatty acid-induced ER stress and lipid accumulation in hepatocytes via AMPK activation. Acta Pharmacol Sin. 2017;38(7):1998–1008.

171. Wang Z, Zou Y, Zhang Y, Zhang J, Ji T, Li W, et al. Protective effects of AS-IV on diabetic cardiomyopathy by improving myocardial lipid metabolism in rat models of T2DM. Biomed Pharmacother. 2020;127:110881.

172. Luo D, Dong X, Huang J, Huang C, Fang G, Huang Y. Pueraia lobata root polysaccharide alleviates glucose and lipid metabolic dysfunction in diabetic db/db mice. Pharm Biol. 2021;59(1):382–90.

173. Cui X, Wang S, Cao H, Guo H, Li Y, Xu F, et al. A review: The bioactivities and pharmaceutical applications of Polygonatum sibiricum polysaccharides. Molecules. 2018;23(5):1170.

174. Li S, Sun T, Zhang H, Li J, Liu Y, Dai W, Fang J, et al. Phytochemical properties and immunological activities of polysaccharides from both crude and wine-processed Polygonatum sibiricum. Int J Biol Macromol. 2020;143:255–64.

175. Yelithao K, Surayot U, Park W, Lee S, Lee DH, You S. Effect of sulfation on the antioxidative effect on a streptozotocin-induced mouse model of diabetes. Mol Med Rep. 2018;18(6):5511–9.

176. Shahrahian MH. A review of Astragalus species as foodstuffs, dietary supplements, a traditional Chinese medicine and a part of modern pharmaceutical science. Appl Ecol Environ Res. 2019;17(6):13371–82.

177. Zhang L, Liu HK, Hsiao PC, Kuo LM, Lee J, Wu TS, et al. New isoflavono- noid glycosides and related constituents from astragali radix (Astragalus membranaceus) and their inhibitory activity on nitric oxide production. J Agric Food Chem. 2011;59(4):1131–7.

178. Gong AGW, Duan R, Wang HY, Kong XP, Dong TTX, Tsim KWK, et al. Evaluation of the pharmaceutical properties and value of Astragali Radices. (Basel). 2018;5(2):46.

179. Song JZ, Yu HH, Qiao CF, Han QB, Xu HX. Chemical comparison and classification of Radix Astragali by determination of isoflavonoids and astragalosides. J Pharm Biomed Anal. 2008;47(2):399–406.

180. Fu J, Wang Z, Huang L, Zheng S, Wang D, Chen S, et al. Review of the botanical characteristics, phytochemistry, and pharmacology of Astragalus membranaceus (Huangqi). Phytother Res. 2014;28(9):1275–83.

181. Zhang CH, Yang X, Wei JR, Chen NM, Xu JP, Bi YQ, et al. Ethnopharmacol- ogy, phytochemistry, pharmacology, toxicology and clinical applications of Radix Astragali. Chin J Integr Med. 2021;27(3):229–40.

182. Su HF, Shaker S, Kuang Y, Zhang M, Ye M, Qiao X. Phytochemistry and cardiovascular protective effects of Huang-Qi (Astragalus Radix). Med Res Rev. 2021;41(4):1999–2036.

183. Wang Z, Li XL, Hong KF, Zhao TT, Dong RX, Wang WM, et al. Total flavonoids of Astragalus ameliorated bile acid metabolism dysfunction in diabetes mellitus model. Evid Based Complement Alternat Med. 2021;2021:6675567.
195. Hou B, Zhao Y, Qiang G, Yang X, Xu C, Chen X, et al. Puerarin mitigates diabetic hepatic steatosis and fibrosis by inhibiting TGF-beta signaling pathway activation in type 2 diabetic rats. Oxid Med Cell Longev. 2018;2018:4545321.

196. Rao Y, Wen Q, Liu R, He M, Jiang Z, Qian K, et al. PL-S2, a homogeneous polysaccharide from Radix Puerariae lobatae, attenuates hyperlipidemia via farnesoid X receptor (FXR) pathway-activated bile acid metabolism. Int J Biol Macromol. 2020;165(Pt B):1694–705.

197. Ju MS, Kim HG, Choi JG, Ryu JH, Hur J, Kim YJ, et al. Cassiae Semen, a seed of Cassia obtusifolia, has neuroprotective effects in Parkinson’s disease models. Food Chem Toxicol. 2010;48(9):–9.2017–44.

198. Dong YJ, Jiang YQ, Liu Y, Chen JP, Gai XH, Tian CW, et al. Research progress on chemical composition and pharmacological effects of Cassiae Semen and predictive analysis on quality markers. Chin Tradit Herbal Drugs. 2021;52(09):2719–32.

199. Yu F, Sun L, Xu L, Xiao P, Miao J. Research progress on modern application of Cassiae Semen. Mod Chin Med. 2018;20(05):62–30.

200. Dong X, Fu J, Yin X, Yang C, Zhang X, Wang W, et al. Cassiae Semen: a review of its phytochemistry and pharmacology. (Review). Mol Med Rep. 2017;16(3):2331–46.

201. Zhu Z, Zhang S, Zheng Y. Effect of extracts of Cassiae Semen on lipid, liver and kidney function in hyperlipidemia rats. Prev Med. 2021;131(12):1290–4.

202. Qi ZL, Bian Y, Cai HQ, Li X, Zhang Y. Effects of Semen Cassiae extract to blood lipid level of hyperlipidemia rats. J Harbin Med Univ. 2018;52(01):19–23.

203. Luo H, Wu H, Wang L, Xiao S, Lu Y, Liu C, et al. Hepatoprotective effects of Cassiae Semen on mice with non-alcoholic fatty liver disease based on gut microbiota. Commun Biol. 2021;4(1):1357.

204. Meng Y, Yu Y, Fan G, Guo Y. Hepatoprotective effects of Cassiae Semen ethanol extract on non-alcoholic fatty liver disease in experimental rats. Pharm Biol. 2019;57(1):98–104.

205. Xu P, Sun X, Huang Y, Shan Y, Wu Y. Research progress on lipid lowering effective components of semen Cassiae. Chin Arch Tradit Chin Med. 2018;36(01):150–3.

206. Li Y, Hou W, Wu J, Song B, Chen W. The affection of cassia glycosides on SREBP-1c and PPARβ in liver of non-alcoholic fatty liver disease rats. Med J West Chin. 2019;31(10):1511–6.

207. Ma J, Liu Y, Yu J, Sun J. Effect of 1, 8-Dihydroxyanthraquinone on the imbalance of lipid metabolism via regulation of expression of CYP7A1 and 3-hydroxy-3-methylglutaryl coenzyme a reductase mRNA in hyperlipidemic mice. Pharmacogn Mag. 2021;17(75):499–504.

208. Vadivel V, Doss A, Pugalenthi M. Evaluation of nutritional value and phytochemical profile of immature sword bean pod (Canavalia gladiata (Jacq.) DC.) based on ancient and modern chemical characterization of peach (Prunus persica) kernel flour. J Food Process Eng. 2011;34(4):1235–65.

209. Hao E, Pang G, Du Z, Lai YH, Chen JR, Xie J, et al. Peach kernel oil downstream regulates expression of tissue factor and reduces atherosclerosis in ApoE knockout mice. Int J Mol Sci. 2019;20(2):405.

210. Iranshahy M, Javadi I, Iranshahi M, Jahanbakhsh SP, Mahyari S, Hassani FV, et al. A review of traditional uses, phytochemistry and pharmacological effects of Peach Kernel. Liaoning J Tradit Chin Med. 2015;42(04):888–90.

211. Wang Y, Jia Q, Zhang Y, Wei J, Liu P. Amygdalin attenuates atherosclerosis and plays an anti-inflammatory role in ApoE knock-out mice and bone marrow-derived macrophages. Front Pharmacol. 2020;11(174):59929.

212. Pelentir N, Block JM, Monteiro Fritz AR, Reginatto V, Amante ER. Production and chemical characterization of peach (Prunus persica) kernel flour. J Food Process Eng. 2011;34(4):1235–65.

213. Shen Y, Yang J, Liu Y, Li B, Liu Y, et al. Amygdalin ameliorates the progression of atherosclerosis in LDL receptordeficient mice. Mol Nutr Food Res. 2017;61(8):1600895.

214. Im AR, Kim YH, Kim YH, Yang WK, Kim SH, Song KH. Dolichos lablab protects against non-alcoholic fatty liver disease in mice fed high-fat diets. J Med Food. 2020;2017(02):22–30.

215. Singh V, Kudesia R. Review on taxonomical and pharmacological status of Dolichos lablab. Curr Trends Biotechnol Pharm. 2020;14(02):229–35.

216. Suh DH, Lee HW, Jung ES, Singh DJ, Kim SH, Lee CH. In vivo metabolomic interpretation of the anti-obesity effects of hycathin bean (Dolichos lablab L.) administration in high-fat diets. J Nutr Food. 2017;61(8):1600895.
paraoxonase-1 activity, in rats fed cholesterol enriched-diet. Nutr Santé. 2017;05(02):107–14.

239. Jung JH, Hwang SB, Park HJ, Jin GR, Lee BH. Antiobesity and antidiabetic effects of Portulaca oleracea powder intake in high-fat diet-induced obese C57BL/6 mice. Evid Based Complement Alternat Med. 2021;2021:5587848.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.